UNITED STATES CONTINUING UTILITY PATENT APPLICATION

under 37 C.F.R. § 1.53(b)

Atty. Docket No. 3094.77432

Assistant Commissioner of Patents
Box Patent Applications
Washington, D.C. 20231

Enclosed herewith is a continuing patent application and the following papers:

First Named Inventor (or application identifier): Chang Yong HONG et al.

Title of Invention: **7-(4-AMINOMETHYL-3-METHYLOXYIMINOPYRROLIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID AND THE PROCESS FOR THE PREPARATION THEREOF**

- ■ Continuation
- ☐ Divisional
- ☐ Continuation-in-Part

of prior application No. 09/049,024, filed March 27, 1998

1. ■ Specification 145 pages (including specification, claims, abstract) / 12 claims (2 independent)

2. ■ Declaration/Power of Attorney:
   - ■ Copy from Prior Application (for continuation or divisional application)
   - ☐ Newly Executed Declaration (for CIP application)
   - ☐ Deferred under 37 C.F.R. § 1.53(f)
   - ☐ Deletion of Inventor(s) - Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b)
   - ■ Incorporation by Reference - The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein

3. ■ 10 Distinct Sheets of ■ Formal ☐ Informal Drawings.

4. ■ Preliminary Amendment

5. ■ Information Disclosure Statement
   - ■ Form 1449
   - ☐ A copy of each cited prior art reference
   - ■ Information Disclosure Statement filed in prior application.

6. ■ Assignment
   - ☐ Assignment with Cover Sheet attached
   - ■ Assignment filed in prior application. Application assigned to:

   LG Chemical Ltd.

UNITED STATES CONTINUING UTILITY PATENT APPLICATION

under 37 C.F.R. § 1.53(b)

7. ■ Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)
Republic of Korea	94-13604	16 June 1994
Republic of Korea	94-39915	30 December 1994
Republic of Korea	94-39930	30 December 1994

8. ■ Priority document(s)
   - ■ were filed in prior application

9. ☐ Small Entity Statement
   - ☐ Small Entity Statement was filed in prior application, Small Entity Status is still proper and desired
   - ☐ is attached
   - ☐ is no longer claimed

10. ☐ Microfiche Computer Program (Appendix)

11. ☐ Nucleotide and/or Amino Acid Sequence Submission
   - ☐ Computer Readable Copy
   - ☐ Paper Copy (identical to computer copy)
   - ☐ Statement verifying identity of above copies

12. Calculation of Fees:

FEES FOR	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			$790.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	0	22.00	$0.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	0	82.00	$0.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	0	270.00	$0.00
Subtotal - Filing Fee Due			$790.00
	MULTIPLY BY		
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0		$0.00
TOTAL FILING FEE DUE			$790.00
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	$0.00
GRAND TOTAL DUE			**$790.00**

UNITED STATES CONTINUING UTILITY PATENT APPLICATION

under 37 C.F.R. § 1.53(b)

13. PAYMENT is:

■ included in the amount of the GRAND TOTAL by our enclosed check. A general authorization under 37 C.F.R. § 1.25(b), second sentence, is hereby given to credit or debit our Deposit Account No. 19-0733 for the instant filing and for any other fees during the pendency of this application under 37 C.F.R. §§ 1.16, 1.17 and 1.18

☐ not included, but deferred under 37 C.F.R. § 1.53(f).

14. All correspondence for the attached application should be directed to:

Banner & Witcoff, Ltd.
1001 G Street, N.W.
Washington, D. C. 20001-4597
Telephone: (202) 508-9100
Facsimile: (202) 508-9299

15. Other: _____

Date: November 9, 1998

By: _____
Susan A. Wolffe
Reg. No. 33,568

SAW/ss

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Chang Yong HONG et al. Atty. Docket: 03094.77432

Continuation of
Serial No.: 09/049,024
filed: March 27, 1998

For: **7-(4-AMINOMETHYL-3-METHYLOXYIMINOPYRROLIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID AND THE PROCESS FOR THE PREPARATION THEREOF**

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination and calculation of claim fees, please amend the instant application as follows:

IN THE SPECIFICATION:

Please insert the following sentence prior to the first paragraph of the specification --This application is a continuation of Serial No. 09/049,024, filed March 27, 1998, which is a divisional of Serial No. 08/825,592, filed April 4, 1997, now U.S. Patent 5,776,944, which is a continuation-in-part of 08/490,978 filed June 15, 1995, now US Patent 5,633,992.--

IN THE CLAIMS:

Please cancel claims 1-16 and add new claims 17-28.

--17. A method for prophylaxis or treatment of bacterial infections in a warm blooded animal, comprising administering an effective amount of the compound 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid of the following formula:



or a pharmaceutically acceptable non-toxic salt, physiologically hydrolyzable ester, or isomer thereof.

18. The method according to claim 17 wherein the compound is in the form of Z-isomer.

19. The method according to claim 17 wherein the compound is administered once a day.

20. The method according to claim 17 wherein the warm blooded mammal is a human being.

21. A method for prophylaxis or treatment of bacterial infections in a warm blooded animal, comprising administering 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate or a hydrate thereof of the following formula:



$\cdot CH_3SO_3H \cdot nH_2O$

in which n is 0, 1, 1.5, 2.5, 3, 3.5 or 4, or an isomer thereof.

22. The method according to claim 21 wherein the compound is in the form of Z-isomer.

23. The method according to claim 21 wherein n is 3.

24. The method according to claim 21 wherein the compound has a moisture content of from 9 to 11% by weight.

25. The method according to claim 21 wherein n is 1.5.

26. The method according to claim 21 wherein the compound has a moisture content of from 4 to 6% by weight.

27. The method according to claim 21 wherein the compound is administered once a day.

28. The method according to claim 21 wherein the warm blooded animal is a human being.--

REMARKS

Examination on the merits of the remaining claims is earnestly solicited.

Respectfully submitted,



Susan A. Wolffe
Reg. No. 33,568

Date: November 9, 1998

BANNER & WITCOFF, LTD.
Eleventh Floor
1001 G Street, N.W.
Washington, D. C. 20001-4597
(202) 508-9100
SAW/ss

7-(4-AMINOMETHYL-3-METHYLOXYIMINOPYRROLIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID AND THE PROCESS FOR THE PREPARATION THEREOF

CROSS-REFERENCE TO RELATED APPLICATION

This is a continuation-in-part of copending U.S. patent applicaton serial No. 08/490,978 filed June 15, 1995.

BACKGROUND OF INVENTION

1. Field of Invention

The present invention relates to a novel quinoline(naphthyridine) carboxylic acid derivative having an excellent antibacterial activity. More specifically, the present invention relates to a novel quinoline(naphthyridine)carboxylic acid derivative represented by the following formula (I), which has an 4-aminomethyl-3-oximepyrrolidine substituent on 7-position of the quinolone nucleus and shows a superior antibacterial activity in contrast to the known quinolone antibacterial agents and also has a broad antibacterial spectrum and a highly improved pharmacokinetic property:



(I),

and its pharmaceutically acceptable non-toxic salt, its physiologically hydrolyzable ester, solvate and isomer, in which

R represents hydrogen, methyl or amino;

Q represents C-H, C-F, C-Cl, C-OH, C-CH_3, C-O-CH_3 or N;

R_1 represents cyclopropyl, ethyl, or phenyl which is substituted with one or more fluorine atom(s);

R_2 represents one of the following a) through e):

a) hydrogen, straight or branched C_1-C_4 alkyl, cyclopropyl, cyclopropylmethyl, C_3-C_6 alkynyl, 2-haloethyl, methoxymethyl, methoxycarbonylmethyl, aryl or allyl,

b) a group of the following formula (1),



(1)

wherein X represents hydrogen, 2, 3 or 4-fluoro, cyano, nitro, methoxy, C_1-C_4 alkyl, or 2,4-difluoro,

c) a group of the following formula (2),



(2)

d) a heteroarylmethyl of the following formula (3),

(3)



e) a group of the following formula (4),

(4)

wherein n denotes 0 or 1, m denotes 0, 1 or 2, and X represents methylene, O or N, and

R_3 and R_4 independently of one another represent hydrogen or C_1-C_3 alkyl or R_3 and R_4 together with a nitrogen atom to which they are attached can form a ring.

The present invention also relates to a process for preparing the compound of formula (I), as defined above, and an antibacterial composition comprising the compound of formula (I) as an active component.

2. Background Art

Since in 1962 nalidixic acid was first introduced as an agent for treating urinary tract infection (see, G. Y. Lesher, et al., J. Med. Chem. 5, 1063-1065 (1962)), numerous quinoline carboxylic acid antibacterial agents, including oxolinic acid, rosoxacin, pipemidic acid, etc., have been developed. However, these early-stage antibaterial agents have a little activity against gram-positive bacterial strains and thus have been used only against gram-negative strains.

Recently, norfloxacin which is the quinolone compound having a fluorine on 6-position has been newly developed (see, H. Koga, et al., J. Med. Chem., 23, 1358-1363 (1980)), and thereafter an

extensive study to develop various quinolone antabacterial compounds has been conducted. However, since norfloxacin has a weak antibacterial activity against gram-positive strains and shows poor distribution and absorption in living body, it has been used only for treatment of diseases including urinary tract infections, gastro-intestinal infections, sexually transmitted diseases and the like. Thereafter, ciprofloxacin (see, R. Wise, et al., J. Antimicrob. Agents Chemother., 23, 559 (1983)), ofloxacin (see, K. Sata, et al., Antimicrob. Agents Chemother., 22, 543 (1982)) and the like have been developed. These antibacterial agents have a superior and broad antibacterial activity in comparison with the early-stage antibacterial compounds, and therefore, have been widely and practically used for treatment of diseases in clinical field.

The compounds in use or under clinical test include mainly the derivatives having a piperazine substituent on 7-position of the quinolone nucleus as in ciprofloxacin or ofloxacin. However, as a result of the study to develop quinolone compounds having a more potent and broad antibacterial activity it has been disclosed that a compound having an 3-amino or 3-aminomethylpyrrolidine group introduced into 7-position has an increased activity against gram-positive strains, in comparison with the compounds having 7-piperazine group, while maintaining a potent activity against gram-negative strains. However, unfortunately, the compounds having pyrrolidine substituent have a low solubility in water in comparison with the compounds having piperazine

substituent, and thus their in-vivo antibacterial activity is not so high as the in-vitro activity. Accordingly, numerous study has been continuously conducted to improve the disadvantage of the compounds having pyrrolidine substituent, that is, to increase the solubility in water and to improve the pharmacokinetic property.

As a result, many reports of such study have been made. For example, it has been disclosed that ((2S, 4S)-4-amino-2-methylpyrrolidinyl)naphthyridine derivatives (see, Rosen, T., Chu, D. T. W. etc. J. Med. Chem. 1988, 31, 1598-1611) or (trans-3-amino-4-methylpyrrolidinyl)naphthyridine derivatives (see, Matsumoto, J. et al., Proceedings of the 14th International Congress of Chemotherapy; Ishigami, J., Ed.; University of Tokyo Press: Tokyo, 1985; pp 1519-1520) shows a 20 to 40 times increase in water-solubility, an increased bioavailability and an improved pharmacokinetic property, in comparison with the compounds having no methyl group, with a similar in-vitro antibacterial activity.

In addition, an attempt to improve the disadvantage of the prior quinolone compounds including a relatively low antibacterial activity against gram-positive strains, a low water-solubility and a poor pharmacokinetic property has been made by introducing different functional groups, instead of amino group, into the pyrrolidine or piperazine moiety. As one of such attempt, some compounds having an oxime group introduced into the 7-amine moiety of quinolone compounds have been reported. For example,

the researchers of Abbott have reported in a scientific journal, J. Med. Chem., 1992, 35, 1392-1398, that the quinolone compound having the following general formula [A] wherein 3-oxime(or methyloxime)pyrrolidine group or 4-oxime(or methyloxime)piperidine group is substituted on 7-position of quinolone nucleus exhibits a good antibacterial activity against gram-positive strains:



[A]

in which

R represents cyclopropyl or 2,4-difluorophenyl;

R' represents hydrogen or methyl;

X represents C-H, C-F or N; and

n denotes 1 or 2.

The compound [A] has some disadvantages that it shows a good antibacterial activity against gram-positive strains but a relatively weak activity against gram-negative strains, and also has a relatively low antibacterial activity in in-vivo test.

In addition, Japanese Laid-open Patent Publication No. (Hei) 01-100165 (1989) discloses the compound having the following general formula [B]:



[B]

in which

R represents cyclopropyl, 2,4-difluorophenyl or 4-hydroxyphenyl;

X represents C-H, C-F or C-Cl; and

R' represents oxime or hydroxyaminopyrrolidine-derived substituent.

Specifically, in said Japanese laid-open publication the oxime or hydroxyaminopyrrolidine-derived groups as R' substituent are very broadly disclosed. However, only the 3-hydroxyaminopyrrolidine [the following formula (a)], 3-methoxyaminopyrrolidine [the following formula (b)], 3-amino-4-methoxyaminopyrrolidine [the following formula (c)], 3-oximepyrrolidine [the following formula (d)] and 3-methyloximepyrrolidine [the following formula (e)] groups are specifically exemplified but the pyrrolidine substituent having both 3-oxime and 4-aminomethyl groups has never been specifically mentioned.



[a] [b] [c]

[d] [e]

Further, European Early Patent Publication No. 0 541 086 discloses the quinolone compound having the following general formula [C]:



[C]

in which

R and R_1 independently of one another represent hydrogen or C_1-C_5 alkyl;

R_2 represents hydrogen, amino, fluoro or hydroxy;

R_3 represents C_3-C_7 cycloalkyl;

R_4 represents methoxy or fluoro;

R_5 and R_6 can be identical with or different from each other and

independently of one another represent hydrogen or alkyl, or R_5 and R_6 together can form C_3-C_5 cycloalkyl;

m denotes 0 or 1; and

n denotes an integer of 1 to 3.

Among the compounds [C] disclosed in said European early patent publication the typical substituent on 7-position of quinolone nucleus is a group having the following structure:



However, the compound of formula [C] does not include any compound having both oxime group and aminomethyl group on 7-position, and therefore, is different from the compound of the present invention.

The common characteristic feature of the known oxime or hydroxyamine-derived compounds as mentioned above is that they exhibit a good activity against gram-positive strains including MRSA (Methicillin Resistant Staphylococcus aureus) strains in comparison with the early developed quinolone compounds but show a weak activity against gram-negative strains in comparison with

the antibacterial agents including ofloxacin or ciprofloxacin. Therefore, it can be said that their antibacterial spectrum may be narrower than that of the known ofloxacin or ciprofloxacin antibacterial compound.

Thus, on the basis of prior art as mentioned above the present inventors have extensively studied to develop the novel oxime-aminomethyl compound, which shows a potent antibacterial activity against broad spectrum pathogenic strains including resistant strains and also exhibits more improved pharmacokinetic properties and high absorption in living body, by introducing various substituted pyrrolidine groups into 7-position of quinoline nucleus and determining pharmacological activities of the resulting compounds. As a result, we have identified that the quinolone compounds having the general formula (I), as defined above, wherein 4-aminomethyl-3-(optionally substituted)oxime-pyrrolidine group is introduced into 7-position of quinoline nucleus can satisfy such purpose, and thus completed the present invention.

Therefore, it is an object of the present invention to provide a novel quinoline(naphthyridine) carboxylic acid derivative of formula (I), as defined above, which shows a potent antibacterial activity against broad pathogenic strains including both gram-positive and gram-negative strains and also has a good pharmacokinetic property.

It is another object of the present invention to provide a

process for preparing the novel quinoline(naphthyridine) carboxylic acid derivative of formula (I).

It is a further object of the present invention to provide an antibacterial composition comprising the novel quinoline (naphthyridine)carboxylic acid derivative of formula (I) as an active component.

BRIEF DESCRIPTION OF THE DRAWINGS

For a thorough understanding of the nature and objects of the invention, reference should be made to the following detailed description taken in connection with the accompanying drawings in which :

Figure 1 represents the moisture adsorption velocity profile of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate at 25°C;

Figure 2 represents the isothermal moisture adsorption profile of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate at 25°C;

Figure 3 represents the equilibrium moisture content of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate·3 hydrate at a relative humidity of 23 to 75%;

Figure 4 represents test result on moisture adsorption of 7-

(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate·1.5 hydrate;

Figure 5 represents the powder X-ray diffraction pattern of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate anhydride;

Figure 6 represents the powder X-ray diffraction pattern of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate·3 hydrate;

Figure 7 represents the powder X-ray diffraction pattern of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate·1.5 hydrate;

Figure 8 represents the variation in moisture content with elapsed time of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate anhydride taken after 0, 5, 10, 20, 30, and 60 minutes, respectively, from the initial point while being passed through with humidified nitrogen;

Figure 9 represents the results of Differential Scanning Calorimetry on 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-

carboxylic acid methanesulfonate anhydride and 3 hydrate;

Figure 10 represents the results of thermogravimetric analysis on 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate·3 hydrate.

DISCLOSURE OF INVENTION

In one aspect, the present invention relates to a novel quinoline(naphthyridine) carboxylic acid derivative having the following formula (I):



(I)

and its pharmaceutically acceptable non-toxic salt, its physiologically hydrolyzable ester, solvate and isomer, in which

R represents hydrogen, methyl or amino;

Q represents C-H, C-F, C-Cl, C-OH, C-CH_3, C-O-CH_3 or N;

R_1 represents cyclopropyl, ethyl, or phenyl which is substituted with one or more fluorine atom(s);

R_2 represents one of the following a) through e):

a) hydrogen, straight or branched C_1-C_4 alkyl, cyclopropyl, cyclopropylmethyl, C_3-C_6 alkynyl, 2-haloethyl, methoxymethyl, methoxycarbonylmethyl, aryl or allyl,

b) a group of the following formula (1),



(1)

wherein X represents hydrogen, 2, 3 or 4-fluoro, cyano, nitro, methoxy, C_1-C_4 alkyl, or 2,4-difluoro,

c) a group of the following formula (2),



(2)

d) a heteroarylmethyl of the following formula (3),

(3)



e) a group of the following formula (4),



(4)

wherein n denotes 0 or 1, m denotes 0, 1 or 2, and X represents methylene, O or N, and

R_3 and R_4 independently of one another represent hydrogen or C_1-C_3 alkyl or R_3 and R_4 together with a nitrogen atom to which they are attached can form a ring.

Among the compound of formula (I), as defined above, having a superior antibacterial activity, a broad antibacterial spectrum and an excellent pharmacokinetic property, the preferred compounds include those wherein Q represents C-H, C-F, C-Cl, C-OMe

or N, R represents hydrogen or amino, R_1 represents cyclopropyl or 2,4-difluorophenyl, R_2 represents hydrogen, methyl, ethyl, isopropyl, t-butyl, phenyl, propargyl, homopropargyl, 2-fluoroethyl, benzyl, 2-fluorobenzyl or 2-cyanobenzyl, and R_3 and R_4 represent hydrogen.

More preferred compounds of formula (I) include those wherein Q represents C-H, C-Cl, C-F or N, R represents hydrogen or amino, R_1 represents cyclopropyl, R_2 represents methyl, t-butyl, homopropargyl, 2-fluoroethyl, benzyl or 2-fluorobenzyl, and R_3 and R_4 represent hydrogen.

In the pyrrolidine moiety of the compound of formula (I) the 4-carbon atom on which aminomethyl group is substituted is an assymetric carbon atom and thus can be present in the form of R or S or a mixture of R abd S. In addition, due to the presence of (optionally substituted) oxime group on 3-position of pyrrolidine moiety the compound of formula (I) can be present in the form of syn- and anti-isomers depending on their geometric structure. Thus, the present invention also includes all of those geometric isomers and their mixtures.

The compound of formula (I) according to the present invention can form a pharmaceutically acceptable non-toxic salt. Such salt includes a salt with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, etc., a salt with organic carboxylic acids such as acetic acid, trifluoroacetic acid, citric acid, maleic acid, oxalic acid,

succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid or malic acid or with sulfonic acids such as methanesulfonic acid, para-toluenesulfonic acid, etc., and a salt with other acids which are generally known and conventionally used in the technical field of quinolone-based compounds. These acid-addition salts can be prepared according to a conventional conversion method.

Particularly, the present invention relates to the 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and its hydrate represented by the following formula (H),



$\cdot CH_3SO_3H \cdot nH_2O$ (H)

in which n denotes 0, 1, 1.5, 2, 2.5, 3, 3.5 or 4, having an improved bioavailability.

The methanesulfonate and its hydrate as defined above exhibit the same potent antibacterial activity as the free form, also have desirable physicochemical properties such as excellent solubility, constant moisture content, etc. regardless of the ambient relative humidity.

Gererally, conversion of a pharmacologically active compound

into a salt form induces a change in the compound's physicochemical properties such as solubility, absorption velocity, etc. Therefore, study about an effective salt form for developing a successful new medicine has been conventionally made. Pharmaceutically more desirable crystal form may be selected by studying whether or not any pseudopolymorph can be produced and its physicochemical properties (see, Remington's Pharmaceutics, Chapter 75 Preformulation; Byrn, S.R. Solid Chemistry of Drugs, Academic Press, New York, 1982). The hydrate, one such pseudopolymorph, has water molecules inside the crystal, and thus has a crystalline structure different from that of the anhydride, as can be verified from their respective X-ray diffraction patterns. A pseudopolymorph differs from the original compound not in its chemical properties, such as pharmacological activity, but in its physical properties, such as crystallinity, hygroscopicity, melting point, solubility, solubilizing velocity, etc. So, the pseudopolymorph has been recognized as pharmaceutically important (see, Morris, K.P. et al., Int. J. Pharm., 108, 15-206 (1994)).

In the process of identifying the physicochemical properties of methanesulfonate, the salt has been found to exist as a stable hydrate when the number of water molecules contained in one molecule varies within a specific range. Here, stability does not mean chemical stability but the difficulty of recovering water molecules. That is, a stable hydrate neither loses the water molecules contained therein nor absorbs moisture over a wide range of ambient relative humidity. In contrast, moisture ab-

sorption by the anhydride varies greatly with the ambient relative humidity. As a result of experiments carried out by the present inventors, 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate has been shown to exist as a stable hydrate for values of the hydration number n equal only to 1, 1.5, 2, 2.5, 3, 3.5 or 4. Among these, 3 is preferred, since the change of moisture content is lowest at that hydration number.

The moisture content of the hydrate varies with the hydration number (n) of the hydrated molecule. Since the molecular weight of 7-(4-amino-methyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate is 485.5, the moisture content of the hydrate for n equal to 1, 1.5, 2, 2.5, 3, 3.5 or 4 is calculated to be 3.6%, 5%, 6.9%, 8.5%, 10.0%, 11.5% or 12.9%, respectively. However, the actual moisture content may differ from the calculated moisture content depending on differences in recrystallization conditions, drying conditions, etc. The range of the actual moisture content for each hydration number is shown in the following Table A.

Table A. Moisture Content according to Hydration Number

Hydration Number (n)	Moisture Content (%)
1	2 - 4
1.5	4 - 6
2	6 - 8
2.5	8 - 9
3	9 - 11
3.5	11 - 12
4	12 - 13

If two or more hydrates having different moisture contents are mixed together, mixtures having a new moisture content by weight, for example, a mixture of 1 hydrate and 1.5 hydrate having a moisture content of 2 to 6%; a mixture of 1.5 hydrate and 2 hydrate having a moisture content of 4 to 8%; a mixture of 2 hydrate and 2.5 hydrate having a moisture content of 6 to 9%; a mixture of 2.5 hydrate and 3 hydrate having a moisture content of 8 to 11%; a mixture of 3 hydrate and 3.5 hydrate having a moisture content of 9 to 12%; or a mixture of 3.5 hydrate and 4 hydrate having a moisture content of 11 to 13%, can be obtained.

It has also been found that the relative humidity range at which the moisture content of each hydrate can be maintained constant differ from each other. That is, although the 3 hydrate has a constant moisture content at a relative humidity of 23 to

1.5 hydrate is constant at a relative humidity of 23 to 64% only (see, Figures 3 and 4).

In the second aspect, the present invention also relates to a process for preparing the novel compound of formula (I).

According to the present invention, the compound of formula (I) can be prepared by reacting a compound of formula (II) with a compound of formula (III) or a salt thereof, as shown in the following reaction scheme 1.

Reaction Scheme 1



In the above scheme,

R, R_1, R_2, R_3, R_4 and Q are defined as previously described; and

X represents a halogen atom, preferably chlorine, bromine or fluorine.

According to the above reaction scheme 1, the compound of formula (I) according to the present invention can be prepared by stirring the compound of formula (II) and the compound of formula (III) in the presence of a solvent for 1 to 20 hours at the temperature between room temperature and 200°C with the addition of a suitable base. In this reaction, the compound of formula (III) can be used in the form of a free compound or a salt with an acid such as hydrochloric acid, hydrobromic acid or trifluoroacetic acid.

As the solvent for the above reaction, any solvent which does not adversely affect the reaction can be used. Preferably, acetonitrile, dimethylformamide(DMF), dimethylsulfoxide(DMSO), pyridine, hexamethylphosphoramide(HMPA), N-methylpyrrolidinone, ethanol, and aqueous mixtures thereof can be used.

This reaction is generally conducted in the presence of an acid acceptor. In this case, to increase the reaction efficiency of the relatively expensive starting material (II) the reactant (III) is used in an excessive amount, for example, an equimolar amount to 10 times molar amount, preferably an equimolar amount to 5 times molar amount, with respect to the starting material (II). When the reactant (III) is used in an excessive

amount, the unreacted compound of formula (III) which is retained after the reaction can be recoverd and reused in another reaction. The acid acceptor which can be preferably used in this reaction includes inorganic bases such as sodium hydrogen carbonate, potassium carbonate, etc., and organic bases such as triethylamine, diisopropylethylamine, pyridine, N,N-dimethylaniline, N,N-dimethylaminopyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU), 1,4-diazabicyclo[2.2.2]octane(DABCO), etc.

The compound of formula (I) according to the present invention can also prepared by a method depicted in the following reaction scheme 2, in which a protecing group P is introduced into one of R_3 and R_4 of the compound of formula (III) wherein R_3 and R_4 are hydrogen to prepare the compound of formula (III') wherein the amino group is protected with P, the protected compound of formula (III') is reacted with the compound of formula (II) under the same condition as in the reaction scheme 1, and then the resulting compound of formula (I') is deprotected by removing the protecting group P to form the desired compound of formula (I).

Reaction Scheme 2



In the above reaction scheme,

R, R_1, R_2 and Q are defined as previously described; and

P represents an amino-protecting group.

In the reaction of the above reaction scheme 2, the compound of formula (III') can be used in the form of a free compound or a salt with hydrochloric acid, hydrobromic acid or trifluoroacetic acid, as in the compound of formula (III) used in the reaction scheme 1.

Any protecting group which is conventionally used in the field of organic chemistry and can be readily removed after the reaction without decomposition of the structure of the desired compound can be used as the suitable amino-protecting group P in the compound of formula (III'). The specific example of protecting groups which can be used for this purpose includes formyl, acetyl, trifluoroacetyl, benzoyl, para-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, benzyloxycarbonyl, para-methoxybenzyloxycarbonyl, trichloroethoxycarbonyl,

beta-iodoethoxycarbonyl, benzyl, para-methoxybenzyl, trityl, tetrahydropyranyl, para-nitrobenzoyl, etc.

After the reaction is completed, the amino-protecting group present in the resulting compound of formula (I') can be removed by hydrolysis, solvolysis or reduction depending on properties of the relevant protecting group. For example, the compound of formula (I') is treated in a solvent in the presence or absence of an acid or base at the temperature of 0 to 130°C to remove the protecting group. As the acid which can be used for this purpose, an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc., an organic acid such as acetic acid, trifluoroacetic acid, formic acid, toluenesulfonic acid, etc., or a Lewis acid such as boron tribromide, aluminum chloride, etc., can be mentioned. As the base for this purpose, hydoxide of an alkali or alkaline earth metal such as sodium hydroxide, barium hydroxide, etc., an alkali metal carbonate such as sodium carbonate, calcium carbonate, etc., an alkali metal alkoxide such as sodium methoxide, sodium ethoxide, etc., or sodium acetate, and the like can be used. The reaction can be carried out in the presence of a solvent, for example, water or an organic solvent such as ethanol, tetrahydrofuran, dioxane, ethyleneglycol, acetic acid, etc., or a mixture of such organic solvent and water. If required, this reaction can also be practiced in the absence of any solvent.

In addition, when the protecting group is para-toluene-

sulfonyl, benzyl, trityl, para-methoxybenzyl, benzyloxycarbonyl, para-methoxybenzyloxycarbonyl, trichloroethoxycarbonyl, beta-iodoethoxycarbonyl and the like, such groups can be effectively removed by means of a reduction. Although the reaction condition of the reduction for removing protecting group may be varied with properties of the relevant protecting group, the reduction can be generally carried out with hydrogen gas stream in an inert solvent in the presence of a catalyst such as platinum, palladium, Raney nickel, etc., at the temperature of 10 to 100°C or with metal sodium or metal lithium in ammonia at the temperature of -50 to -10°C.

The compound of formula (II) used as the starting material in the present invention is a known compound and can be readily prepared according to a method known in the prior publication (see, J. M. Domagala, et al., J. Med. Chem. 34, 1142 (1991); J. M. Domagala, et al., J. Med. Chem. 31, 991 (1988); D. Bouzard, et al., J. Med. Chem. 35, 518 (1992)).

The compound of formula (III) used as another starting material in the present invention can be readily prepared according to the method as depicted in the following reaction schemes 3, 4 and 5.

Reaction Scheme 3



[1] [2] [3]

[4] [5]

[6] (III-a)

Reaction Scheme 4



In the above reaction schemes 3 and 4,

the protecting groups P and P' independently of one another represent the same amino-protecting group as defined for P in connection with the compound of formula (III') and can be identical with or different from each other; and

Py represents pyridine.

The process depicted in the reaction schemes 3 and 4 will be specifically explained hereinafter.

According to the reaction scheme 3, first a cyano ester [1] having a protected amino group can be reacted with sodium ethoxide in a solvent such as ethanol to obtain a 3-keto-4-cyanopyrrolidine [2]. The resulting cyanopyrrolidine [2] is reduced with hydrogen gas in the presence of a platinum catalyst to prepare an aminoalcohol [3]. In this case, the cyanopyrrolidine [2] may be reduced by means of other reductant to prepare the aminoalcohol [3]. For example, the ketone and cyano groups

can be reduced with lithium aluminumhydride(LAH), sodium borohydride-cobalt chloride complex($NaBH_4$-$CoCl_3$) or lithium borohydride($LiBH_4$). Alternatively, the aminoalcohol [3] can be synthesized by reducing first the ketone group to a hydroxyl group by means of sodium borohydride($NaBH_4$) and then reducing the cyano group by lithium aluminum hydride(LAH). Then, the amino group of the aminoalcohol [3] thus prepared is selectively protected to obtain a protected amine [4], which is then treated with sulfur trioxide(SO_3)-pyridine mixture in dimethylsulfoxide solvent (see, Parikh, J.R. and Doering, W. v. E. J. Am. Chem. Soc. 1967, 89, 5505), or oxidized with other oxidant, to prepare a ketone compound [5]. The resulting ketone compound [5] is then reacted with a O-substituted hydroxyamine of formula R_2ONH_2 to obtain the desired substituted oxime compound [6], which can be deprotected by means of a suitable method selected depending on the kind of protecting group to obtain the desired oxime compound (III) wherein R_3 and R_4 are hydrogen, i.e. the compound of formula (III-a).

Alternatively, according to the method depicted in the reaction scheme 4, the ketone compound [5] is reacted with hydroxyamine to obtain the desired oxime compound [7] and the compound [7] is reacted with a suitable electrophilic compound of formula R_2X which can introduce the desired R_2 group, in the presence of a base to prepare the oxime derivative of formula [6], which is then deprotected by means of a suitable method selected depending on the kind of protecting group in the same

manner as in the reaction scheme 3 to prepare the desired oxime compound (III-a).

The compound of formula (III) wherein R_3 and R_4 of aminomethyl group present on 4-position of pyrrolidine are other than hydrogen, i.e. the compound of formula (III-b), can be prepared by the following reaction scheme 5.

Reaction Scheme 5



In the above reaction scheme,

R_3' and R_4' represent the same meaning as defined for R_3 and R_4 in connection with the compound of formula (I), provided that they cannot be hydrogen.

According to the method of reaction scheme 5, first the

amine compound [3] is treated with C_1-C_3 aldehyde and then reduced to obtain a substituted amine compound [8] and the resulting amine compound [8] is treated with sulfur trioxide(SO_3)-pyridine mixture in dimethylsulfoxide solvent, or oxidized with other oxidant, to obtain a ketone compound [9]. The resulting ketone compound [9] can be treated in the same manner as in the method for treating ketone compound [5] in the reaction schemes 3 and 4 to synthesize the desired compound of formula (III-b).

The 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate can be prepared by adding the methanesulfonic acid to the corresponding quinolone carboxylic acid compound in an amount of 0.95 to 1.5 times molar amount with respect to the quinolone carboxylic acid compound, or by adding the same amount of the methanesulfonic acid which is already dissolved in a solvent to the quinolone carboxylic acid compound. Although solvents suitable for the above preparation include C_1-C_4 haloalkanes, C_1-C_8 alcohols and water, a solvent selected from the group consisting of dichloromethane, chloroform, 1,2-dichloroe- thane, methanol, ethanol, propanol, and water is preferred. If necessary, the quinolone carboxylic acid compound in a solvent may be heated to dissolve the former before the methanesulfonic acid is added. If the quinolone carboxylic acid compound-solution exists as a suspension, acid may be added to the suspension to obtain a thoroughly transparent solution. The resulting reaction mixture is stirred for 1 to 24 hours at a temperature of

-10 to 40°C or is allowed to stand, then the product is obtained as a solid according as the solubility of the product decreases. The methanesulfonate can also be obtained in a high yield by removing the solvent used under reduced pressure.

The hydrates of the methanesulfonate of the present invention may easily be prepared by means of conventional methods well kown in the art to which the present invention pertains. Particularly, the different hydrates may be prepared merely by changing recrystallization conditions.

The synthetic methods as described above will be more specifically explained in the following preparation examples.

The present invention also provides an antibacterial composition comprising the novel compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof as an active component together with a pharmaceutically acceptable carrier. When such antibacterial composition is used for clinical purpose, it may be formulated into solid, semi-solid or liquid pharmaceutical preparations for oral, parenteral or topical administration by combining the compound of formula (I) with a pahrmaceutically acceptable inert carrier. The pharmaceutically acceptable inert carrier which can be used for this purpose may be solid or liquid. The solid or semi-solid pharmaceutical preparation in the form of powders, tablets, dispersible powders, capsules, cachets, suppositories and ointments may be prepared in which case solid carriers are usually used. The solid carrier which can be used

is preferably one or more substances selected from the group consisting of diluents, flavouring agents, solubilizing agents, lubricants, suspending agents, binders, swelling agents, etc. or may be encapsulating substances. In the case of powder preparation, the micronized active component is contained in an amount of 5 or 10 to 70% in the carrier. Specific example of the suitable solid carrier includes magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectine, dextrin, starch, gelatin, tragaganth, methylcellulose, sodium carboxymethylcellulose, low boiling wax, cocoa butter, etc. Because of their ease in administration, tablets, powders, cachets and capsules represent the most advantageous solid preparation for oral administration.

The liquid preparation includes solutions, suspensions and emulsions. For example, the injectable preparation for parenteral administration may be in the form of water or water-propyleneglycol solution, of which isotonicity, pH and the like can be adjusted to be suited for the physiological condition of living body. The liquid preparation can also be prepared in the form of a solution in aqueous polyethyleneglycol solution. The aqueous solution for oral administration can be prepared by dissolving the active component in water and adding a suitable coloring agent, flavouring agent, stabilizer and thickening agent thereto. The aqueous suspension suitable for oral administration can be prepared by dispersing the micronized active component in viscous substances such as natural or synthetic gum, methylcellulose, sodium carboxymethylcellulose and other known suspending agent.

It is especially advantageous to formulate the aforementioned pharmaceutical preparations in dosage unit form for ease of administration and uniformity of dosage. Dosage unit forms of the preparation refer to physically discrete units suitable as unitary dosage, each unit containing a predetermined quantity of the active component calculated to produce the desired therapeutic effect. Such dosage unit form can be in the packaged form, for example, a tablet, a capsule or a powder filled in vial or ampule, or an ointment, gel or cream filled in tube or bottle.

Although the amount of the active component contained in the dosage unit form can be varied, it can be generally adjusted within the range of 1 to 100mg depending on the efficacy of the selected active component.

When the active compound of formula (I) of the present invention is used as a medicine for treatment of bacterial infections, it is preferably administered in an amount of about 6 to 14mg per kg of body weight at the first stage. However, the administration dosage can be varied with the requirement of the subject patient, severity of the infections to be treated, the selected compound and the like.

The preferred dosage suitable for a certain condition can be determined by a person skilled in this art according to a conventional manner. In general, the therapeutic treatment is started from the amount less than the optimal dosage of the active compound and then the administration dosage is increased

little by little until the optimal therapeutic effect is obtained. As a matter of convenience, the total daily dosage can be divided into several portions and administered over several times.

As mentioned above, the compound of the present invention shows a potent and broad spectrum antibacterial activity against various pathogenic organisms including gram-positive and gram-negative strains. The antibacterial activity of the present compound against gram-negative strains is comparable to or higher than that of the known antibacterial agents (for example, ciprofloxacin), and particularly, the antibacterial activity of the present compound against gram-positive strains is far superior to that of the known antibacterial agents. In addition, the present compound also exhibits a very potent antibacterial activity against the strains resistant to the known quinolone compounds.

In view of the pharmacokinetic properties, the compound of the present invention has a high water-solubility and thus can be well absorbed in the living body, in comparison with the known quinolone compounds, to show a very high bioavailability. The biological half life of the present compound is far longer than that of the known quinolone compounds, and therefore, the present compound can be administered once a day to be suitably used as an antibacterial agent.

Moreover, since the compound according to the present inven-

tion is less toxic, it can be effectively used for prophylaxis and treatment of diseases caused by bacterial infections in warm-blooded animals including human being.

The present invention will be more specifically explained in the following examples. However, it should be understood that the following preparations and examples are intended to illustrate the present invention and not to limit the scope of the present invention in any manner.

Preparation 1

Synthesis of (2-cyano-ethylamino)acetic acid ethyl ester



139.6g (1 mole) of glycine ethyl ester hydrochloride was dissolved in 80ml of distilled water and to this solution was added 230ml of an aqueous solution of 67.3g (1.2 mole eq.) of potassium hydroxide. Then, 106.2g (2 mole eq.) of acrylonitrile was added to the reaction solution while heating and stirring at 50 to 60°C. The reaction mixture was stirred for 5 hours with heating and then the organic layer was separated. The aqueous layer was extracted with ethyl ether and the extract was combined with the organic layer as separated above. The combined organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to remove

the solvent. The residue was distilled under reduced pressure (100 to 150°C/10.25torr) to obtain 65.6g (Yield: 48%) of the title compound.

^1H NMR ($CDCl_3$, ppm) : δ 4.20(2H, q), 3.48(2H, s),
2.96(2H, t), 2.54(2H, t), 1.30(3H, t)

MS (FAB, m/e) : 157(M+H)

Preparation 2

Synthesis of 4-cyano-1-(N-t-butoxycarbonyl)-pyrrolidin-3-one



In the above formula and the following, Boc represents t-butoxycarbonyl. 29g (0.186 mole) of the compound prepared in Preparation 1 was dissolved in 200ml of chloroform and the resulting solution was introduced into a 1 L flask. Then, 45g (1.1 mole eq.) of di-t-butoxycarbonyldicarbonate was added thereto and the reaction mixture was stirred for 17 hours at room temperature. The reaction solution was concentrated and the residue was diluted with 250ml of absolute ethanol. The resulting solution was added to sodium ethoxide (NaOEt) solution prepared by adding 6g of metal sodium (Na) turnings to 220ml of absolute ethanol, under refluxing and heating. The reaction was continuously conducted for further one hour under refluxing with heating. The reaction solution was concentrated under reduced pressure and the residue was diluted with water and then washed

with methylene chloride. The aqueous layer was adjusted with 1N HCl to pH 4 and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated to obtain a stoichiometric amount of the title compound in a crude state.

^{1}H NMR ($CDCl_3$, ppm) : δ 4.5-3.5(5H, m), 1.5(9H, s)

MS (FAB, m/e) : 211(M+H)

Preparation 3

Synthesis of 4-aminomethyl-1-(N-t-butoxycarbonyl)pyrrolidin-3-ol hydrochloride



3g (11 mmole) of the compound prepared in Preparation 2 was dissolved in the mixture of 357ml of absolute ethanol and 7ml of chloroform and the resulting solution was introduced into a flask. Then, a catalytic amount of platinum oxide(PtO_2) was added thereto. After air was removed from the reaction flask under reduced pressure, the reaction mixture was stirred for 17 hours at room temperature with blowing up the hydrogen gas from a balloon filled with hydrogen gas. The reaction solution was filtered and the filtrate was concentrated to obtain a stoichiometric amount of the title compound.

^{1}H NMR ($CDCl_3$, ppm) : δ 8.0(2H, bs), 3.5-2.0(7H, m),

3.3(2H, s), 1.38(9H, s)

MS (FAB, m/e) : 217(M-H)

Preparation 4

Synthesis of 4-(N-t-butoxycarbonyl)aminomethyl-1-(N-t-butoxycarbonyl)pyrrolidin-3-ol



Method A :

20g (0.094 mole) of the compound prepared in Preparation 3 was dissolved in the mixture of 456ml of dioxane and 260ml of distilled water and the resulting solution was adjusted with 1N aqueous sodium hydroxide solution to pH 9. Then, 30.9g (1.5 mole eq.) of di-t-butoxycarbonyldicarbonate was added thereto, and the reaction mixture was stirred for 30 minutes at room temperature and concentrated under reduced pressure. The residue was diluted with methylene chloride. After adding water to the reaction solution, the organic layer was separated and the aqueous layer was acidified to pH 4 and then extracted with methylene chloride. The extract was combined with the organic layer as separated above and the combined solution was dried over anhydrous magnesium sulfate and concentrated. The residue was purified with column chromatography to obtain 17g (Yield: 57%) of the title compound.

^{1}H NMR ($CDCl_3$, ppm) : δ 4.95(1H, m), 4.1(1H, m), 3.5(2H, m), 3.3-3.0(4H, m), 2.1(1H, m), 1.45(18H, s)

MS (FAB, m/e) : 317(M+H)

Method B :

10g (0.047 mole) of the compound prepared in Preparation 2 was introduced into a 1 L flask and then dissolved by adding 500ml of dry tetrahydrofuran. This solution was cooled to -3°C under ice-sodium chloride bath and then 3.8g (0.094 mole) of lithium aluminumhydride(LAH) was added portionwise thereto over 20 minutes. After the addition is completed, the reaction mixture was stirred for one hour under ice-water bath. When the reaction is completed, 4ml of water, 4ml of 15% aqueous sodium hydroxide solution and 12ml of water were carefully and successively added to the reaction mixture. The whole mixture was vigorously stirred for 3 hours at room temperature and 10g of anhydrous magnesium sulfate was added thereto. This mixture was stirred and then filtered, and the filtrate was concentrated to stoichiometrically obtain the product. The resulting product was diluted with 200ml of dioxane-water (2:1 by volume) and 12.3g (0.056 mole) of di-t-butoxycarbonyldicarbonate was added thereto at room temperature. The reaction solution was stirred for one hour at room temperature to complete the reaction and then concentrated. The residue was diluted again with ethyl acetate, washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated and the residue was then purified with column

chromatography using hexane-ethyl acetate (2:1 by volume) eluant to obtain 8.2g (Yield: 55%) of the title compound.

Method C :

210g (1 mole) of the compound prepared in Preparation 2 was dissolved in 4 L of methanol and this solution was introduced into a 6 L reaction vessel equipped with a thermometer. The internal temperature of the reaction vessel was cooled to 10°C under dry ice-acetone bath. 76g (2 mole) of sodium borohydride ($NaBH_4$) was added portionwise thereto over 1.5 hours while maintaining the internal temperature of the vessel at 10 to 13°C. After the addition is completed, the reaction mixture was stirred for further 30 minutes at the same temperature so that all the ketone can be reduced to alcohol. Then, 243g (1 mole) of cobalt chloride hydrate was added thereto over 10 minutes. When the reaction is completed, the resulting solid complex was dissolved in 4 L of ammonia water and this solution was diluted with 8 L of water and then extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated and mixed with the mixture of 1.5 L of dioxane and 0.5 L of distilled water. 218g of di-t-butoxycarbonyldicarbonate was added thereto and the whole mixture was stirred for 2 hours at room temperature. After the reaction is completed, the reaction mixture was concentrated under reduced pressure, diluted again with dichloromethane, washed with water, dried over anhydrous magnesium sul-

fate and then filtered. The filtrate was concentrated and then purified with silica gel column chromatography (eluant: hexane-ethyl acetate 2:1 by volume) to obtain 202g (Yield: 64%) of the title compound.

Method D :

10g (0.047 mole) of the compound prepared in Preparation 2 was introduced into a 1 L flask and dissolved by adding 500ml of methanol. This solution was cooled down under ice bath and 3.6g (0.094 mole) of sodium borohydride was added portionwise thereto over 20 minutes. The reaction mixture was stirred for further 30 minutes to complete the reaction, and then concentrated under reduced pressure, diluted with ethyl acetate, washed with water, dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated to obtain the compound in which the desired ketone group is reduced to an alcohol. 10.1g (0.047 mole) of the resulting alcohol compound was dissolved in 200ml of dry tetrahydrofuran and this solution was cooled down to -5°C under ice-salt bath. 2.6g (0.066 mole) of lithium aluminumhydride was added thereto over 20 minutes. The reaction mixture was stirred for further 30 minutes at the same temperature to complete the reaction, and then 2.6ml of water, 2.6ml of 15% sodium hydroxide and 7.8ml of water were added in order thereto. This mixture was stirred for one hour at room temperature. After adding 6g of anhydrous magnesium sulfate, the mixture was stirred for further 30 minutes and filtered. The filtrate was concentrated to obtain the product. The resulting product was

diluted with 200ml of dioxane-water (2:1 by volume) and 12.3g (0.056 mole) of di-t-butoxycarbonyldicarbonate was added portionwise thereto. The mixture was stirred for 30 minutes to complete the reaction, and then concentrated, diluted with ethyl acetate, washed with saturated saline, dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated and the residue was purified with column chromatography to obtain 12.3g (Yield: 83%) of the title compound.

Preparation 5

Synthesis of 4-(N-t-butoxycarbonyl)aminomethyl-1-(N-t-butoxycarbonyl)pyrrolidin-3-one



14g (0.044 mole) of the compound prepared in Preparation 4 was dissolved in 64ml of dimethylsulfoxide and 18.5ml (3 mole eq.) of triethylamine was added thereto. This mixture was cooled down under ice bath. When the wall of reaction flask begins to freeze, 12.7g (1.8 mole eq.) of pyridine-sulfur trioxide($Py-SO_3$) oxidant was added portionwise thereto. After the addition is completed, the ice bath was removed and the reaction solution was stirred for 3 hours at room temperature, diluted with water and then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated to

stoichiometrically obtain the title compound in a crude state.

^1H NMR ($CDCl_3$, ppm) : δ 4.95(1H, bs), 4.15-2.7(6H, m), 2.8 (1H, br), 1.45(9H, s), 1.40(9H, s)

MS (FAB, m/e) : 315 (M+H)

Preparation 6

Synthesis of 1-(N-t-butoxycarbonyl)-4-(N-t-butoxycarbonyl)amino-methyl-pyrrolidin-3-one oxime



300mg of the compound prepared in Preparation 5 was dissolved in the mixture of 6ml of 95% ethanol and 3ml of tetrahydrofuran(THF) and this solution was introduced into a 30ml reaction vessel. 232mg (3.5 mole eq.) of hydroxyamine hydrochloride ($NH_2OH \cdot HCl$) was added thereto and then 281mg (3.5 mole eq.) of sodium hydrogen carbonate dissolved in 1.5ml of distilled water was added. The reaction mixture was stirred for 40 minutes at 40°C under oil bath to complete the reaction, cooled down and then concentrated under reduced pressure. The residue was diluted with methylene chloride, washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated and the residue was subjected to silica gel column chromatography eluting with hexane-ethyl acetate (1:1 by volume) to obtain 230mg (Yield: 73%) of the title compound.

^1H NMR ($CDCl_3$, ppm) : δ 9.70(1H, bs), 5.05(1, bs), 4.2(2H, br), 3.83(1H, m), 3.5-3.2(3H,m), 3.0(1H, m), 1.42(18H, s)

MS (FAB, m/e) : 330(M+H)

Preparation 7

Synthesis of 1-(N-t-butoxycarbonyl)-4-(N-t-butoxycarbonyl)amino-methyl-pyrrolidin-3-one-benzyloxime



659mg of the compound prepared in Preparation 6, 193mg of tetra-n-butylammonium bromide and 855mg of benzyl bromide were added to 15ml of dichloromethane and then 5ml of 15% aqueous sodium hydroxide solution was added thereto. The reaction mixture was stirred for 30 minutes at room temperature. The organic layer was separated, dried over anhydrous magnesium sulfate and filtered. The filtrate was distilled under reduced pressure and the residue was purified with glass column chromatography to obtain 776mg (Yield: 92%) of the title compound.

^1H NMR ($CDCl_3$, ppm) : δ 7.38(5H, m), 5.13(2H, s), 4.92(1H, m), 4.13(2H, m), 3.76(1H, m), 3.41(1H, m), 3.25(2H m), 3.02(1H, m), 1.50(9H, s), 1.49(9H, s)

MS (FAB, m/e) : 420(M+H)

Preparations 8 to 17

The amine compounds listed in the following Table 1 were prepared according to the same procedure as Preparation 7 except that the corresponding benzylbromide derivatives having R_2 structure as presented in the following Table 1 are used instead of benzylbromide.



Table 1. Preparations 8 to 17

Prep.	R_2	NMR($CDCl_3$), δ(ppm)	FAB MS(M+H)
8	4-nitrobenzyl	8.2(2H,m), 7.4(2H,m), 5.2(2H,s), 4.9(1H, s), 4.2(2H,m), 3.8(1H,m), 3.5-3.2(3H,m), 3.0(1H,m), 1.5(18H,s)	465
9	4-methoxybenzyl	7.3(2H,m), 6.9(2H,m), 5.0(2H,s), 4.9(1H, s), 4.1(2H,m), 3.8(3H,s), 3.75(1H,m), 3.5-3.0(4H,m), 1.45(18H,s)	450
10	4-fluorobenzyl	7.3(2H,m), 7.0(2H,m), 5.0(2H,s), 4.8(1H, br), 4.2(2H,m), 3.9(1H,m), 3.4(3H,m), 3.0(1H,m), 1.46(18H,s)	438
11	4-t-butylbenzyl	7.4-7.3(4H,m), 5.1(2H,s), 5.0(1H,s), 4.1(2H,m), 3.8(1H,m), 3.6-3.0(4H,m), 1.45(18H,s), 1.3(9H,s)	476
12	2-cyanobenzyl	7.8-7.3(4H,m), 5.3(2H,s), 5.0(1H,bs), 4.2(2H,s), 3.9(1H,m), 3.6-3.2(3H,m), 3.0(1H,s), 1.5(18H,s)	445
13	3-pyridylmethyl	8.6(2H,m), 7.7(1H,m), 7.3(1H,m), 5.1(2H, s), 4.9(1H,s), 4.1(2H,m), 3.8(1H,m), 3.6-3.2(3H,m), 3.0(1H,m), 1.5(18H,s)	421
14		7.4(2H,m), 6.5(1H,m), 4.9(2H,s), 4.9(1H,s), 4.1(2H,m), 3.8(2H,m), 3.2(3H,m), 1.5(18H,s)	410
15		7.7(2H,m), 7.2(1H,m), 5.5(1H,s), 5.0(1H,s), 4.2(2H,m), 3.8(1H,m), 3.6-3.1(4H,m), 1.5(18H,s)	495
16		6.9(3H,m), 6.0(2H,m), 5.0(3H,m), 4.1(2H,m), 3.8(1H,m), 3.6-3.2(3H,m), 3.0(1H,m), 1.5(18H,s)	464
17		7.3-7.0(3H,m), 6.8(1H,s), 5.1(1H,s), 4.2(2H,m), 3.8(1H,m), 3.5-3.0(4H,m), 1.6-1.4(27H,s)	496

Preparation 18

Synthesis of 4-aminomethyl-pyrrolidin-3-one-benzyloxime dihydrochloride



20ml of methanol was cooled down to 5°C and then 10ml of acetyl chloride was slowly added thereto. This mixture was stirred for 30 minutes and 990mg of the compound prepared in Preparation 7, which is dissolved in 10ml of methanol, was added thereto. The reaction mixture was stirred for 50 minutes at room temperature and concentrated under reduced pressure. The residue was washed with ethyl acetate and dried to obtain 648mg (Yield: 94%) of the title compound as a yellow solid.

^{1}H NMR (DMSO-d_6, ppm) : δ 10.0(1H, m), 8.35(2H, m), 7.40(5H, m), 5.18(2H, s), 4.00(2H, m), 3.69(1H, m), 3.40(2H, m), 3.12(2H, s)

MS (FAB, m/e) : 220(M+H)

Preparations 19 to 28

The compounds listed in the following Table 2 were prepared from the amine compounds prepared in Preparations 8 to 17 according to the same procedure as Preparation 18.



Table 2. Preparations 19 to 28

Prep.	R_2	NMR($CDCl_3$), δ(ppm)	FAB MS(M+H)
19	4-nitrobenzyl	10.3-10.1(2H,s), 8.3(3H,s), 8.2(2H,d), 7.7(2H,d), 5.3(2H,s), 4.1(2H,m), 3.7(1H, m), 3.4(2H,m), 3.1(2H,m)	265
20	4-methoxybenzyl	10.2-10.0(2H,s), 8.4(3H,s), 7.3(2H,d), 6.9(2H,d), 5.0(2H,s), 3.9(2H,m), 3.73(3H, s), 3.7(1H,m), 3.4(2H,m), 3.1(2H,m)	250
21	4-fluorobenzyl	10.2(2H,s), 8.4(3H,s), 7.3(2H,m), 7.2(2H, m), 5.1(2H,s), 3.9(2H,m), 3.7(1H,m), 3.4(2H,m), 3.1(2H,m)	238
22	4-t-butylbenzyl	10.2(2H,s), 8.4(3H,s), 7.4-7.3(4H,m), 5.1(2H,s), 3.9(2H,m), 3.7(1H,m), 3.2 (2H,m), 3.1(2H, m), 1.3(9H,s)	276
23	2-cyanobenzyl	10.2-10.0(2H,s), 8.2(3H,s), 7.9-7.5(4H, m), 5.3(2H,s), 4.0(2H,m), 3.7(1H,m), 3.2(2H,m), 3.1(2H,m)	245
24	3-pyridylmethyl	10.3(1H,s), 10.1(1H,s), 8.9(1H,s), 8.8 (1H,m), 8.5(1H,d), 8.4(3H,m), 8.0(1H,m), 5.4(2H,s), 4.0(2H,m), 3.7(1H,m), 3.4 (2H,m), 3.1(2H,m)	221
25		10.3(2H,s), 8.4(3H,s), 7.6(1H,s), 6.4(1H,s), 5.0(2H,s), 4.0(2H,m), 3.8(1H,m), 3.4(2H,m), 3.1(2H,m)	210
26		10.3(2H,s), 8.3(3H,s), 8.1(1H,m), 7.9 (1H,m), 7.4(1H,m), 5.5(2H,s), 4.1(2H,m), 3.9(1H,m), 3.14(2H,m), 3.1(2H,m)	295
27		10.2(2H,s), 8.3(3H,s), 7.0(3H,m), 6.3 (2H,s), 5.3(2H,m), 4.1(2H,m), 3.9(1H,m), 3.4-3.2(2H,m), 3.1(2H,m)	264
28		10.3-10.2(2H,s), 8.4(3H,s), 8.0-7.3(3H, m), 7.0(1H,s), 4.2(2H,m), 3.8(1H,m), 3.5-3.2(3H,m), 3.0(1H,m)	296

Preparation 29

Synthesis of 1-(N-t-butoxycarbonyl)-4-(N-t-butoxycarbonyl)amino-methyl-pyrrolidin-3-one t-butyloxime



300mg of the compound prepared in Preparation 5 was dissolved in the mixture of 6ml of 95% ethanol and 3ml of tetrahydrofuran(THF) and this solution was introduced into a 30ml reaction vessel. 487mg (3.5 mole eq.) of o-t-butylhydroxyamine hydrochloride was added thereto and then 281mg (3.5 mole eq.) of sodium hydrogen carbonate dissolved in 1.5ml of distilled water was added. The reaction mixture was stirred for 40 minutes at 40°C under oil bath to complete the reaction, and then cooled down, concentrated under reduced pressure, diluted with methylene chloride, washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated and the residue was subjected to silica gel column chromatography eluting with hexane-ethyl acetate (1:1 by volume) to obtain 238mg (Yield: 80%) of the title compound.

^{1}H NMR ($CDCl_3$, ppm) : δ 5.10(1H, bs), 4.05(2H, s), 3.71(1H, dd), 3.43(1H, br), 3.2(2H, m), 3.0(1H, m), 1.42(18H, s), 1.30(9H, s)

MS (FAB, m/e) : 386(M+H)

Preparation 30

Synthesis of 1-(N-t-butoxycarbonyl)-4-(N-t-butoxycarbonyl)aminomethyl-pyrrolidin-3-one 3-butynyloxime



A. Synthesis of 3-butynyl hydroxylamine

0.35g (5 mmole) of 3-butynol, 0.86g (5.25 mmole) of N-hydroxyphthalimide and 1.44g (5.5 mmole) of triphenylphosphine were dissolved in 15ml of dry tetrahydrofuran, and then 1.05g (6 mmole) of diethylazodicarboxylate was added thereto over 30 minutes. The mixture was stirred for 10 minutes at room temperature and then distilled under reduced pressure to remove the solvent. To the residue was added 50ml of ethyl acetate-hexane (1:1 v/v). The precipitated solid material was filtered off and the filtrate was concentrated. The residue was purified with column chromatography (hexane-ethyl acetate 9:1 v/v). The resulting white solid [0.54g, Yield 50%, ^{1}H NMR ($CDCl_3$, ppm) : δ 7.85(2H, m), 7.75(2H, m), 4.2(2H, t), 2.8(2H, dd), 2.5(2H, dd), 2.1(1H, s), FAB MS(POS) : $[M+H]^+$ = 216] was dissolved in 12ml of methylene chloride, and 0.25g (5 mmole) of hydrazine hydrate diluted with 4ml of methanol was added dropwise thereto. The solid precipitate was filtered off and the filtrate was concentrated at low temperature under reduced pressure to obtain 0.2g (Yield: 93%) of the title compound.

^{1}H NMR ($CDCl_3$, ppm) : δ 9.5(2H, br), 4,5(2H, t), 2.8(2H, m), 2.4(2H, m), 2.05(1H, s)

MS (FAB, m/e) : 86$(M+H)^+$

B. Synthesis of the title compound

0.45g (1.43 mmole) of the compound prepared in Preparation 5 and 0.2g (2.35 mmole) of 3-butynyl hydroxyamine were dissolved in 5 ml of methanol and the reaction was conducted for 12 hours at 60°C. The reaction solution was concentrated under reduced pressure and the residue was subjected to column chromatography (ethyl acetate-hexane 1:4 v/v) to obtain 0.59g (stoichiometric amount) of the title compound.

^{1}H NMR ($CDCl_3$, ppm) : δ 5.0(1H, m), 4.15(2H, t), 4.0(2H, s), 3.75(1H, m), 3.6-3.2(3H, m), 3.0(1H, m), 2.5(2H, m), 2.0(1H, s), 1.45(18H, s)

FAB MS (POS) : 382$(M+H)^+$

Preparations 31 to 36

The amine compounds listed in the following Table 3 were prepared according to the same procedure as Preparation 30 except that the corresponding alcohol derivatives having R_2 structure as represented in the following Table 3 are used instead of 3-butynol.



Table 3. Preparations 31 to 36

Prep.	P_2	^1H NMR($CDCl_3$), δ(ppm)	FAB MS(M+H)
31	isopropyl	5.0(1H,br), 4.1(2H,s), 4.0(1H,m), 3.4 (1H,m), 3.55-3.25(3H,m), 3.0(1H,m), 1.55(18H,s), 1.0(6H,d)	372
32	cyclobutyl	4.7(1H,m), 4.2(2H,s), 3.8(1H,m), 3.4(1H, m), 3.3(2H,m), 3.0(1H,m), 2.3(2H,m), 2.1 (2H,m), 1.8(1H,m), 1.6(1H,m), 1.5(18H,s)	384
33	cyclopentyl	4.7(1H,m), 4.1(2H,m), 3.7(1H,m), 3.4(1H,m), 3.3(2H,m), 3.0(1H,m), 1.8(4H,m), 1.7(4H,m), 1.6(18H,s)	398
34		5.0-4.8(1H,m), 4.3-3.7(6H,m), 3.3(2H,m), 3.0(1H,m), 2.1(2H,m), 1.5(18H,s), 1.3(2H,m)	400
35	cyclopropyl-methyl	5.1(1H,br), 4.1(2H,m), 3.9(2H,m), 3.3(1H, m), 3.5(1H,m), 3.3(2H,m), 3.0(1H,m), 1.5 (18H,s), 1.1(1H,m), 0.6(2H,s), 0.3(2H,s)	384
36	isobutyl	5.05(1H,br), 4.15(2H,s), 4.1(2H,d), 3.6(2H,m), 3.3(1H,m), 3.0(2H,m), 2.5(1H,m), 1.5(18H,s), 1.05(6H,d)	386

Preparation 37

Synthesis of 1-(N-t-butoxycarbonyl)-4-(N-t-butoxycarbonyl)amino-methyl-pyrrolidin-3-one propargyl oxime



659mg of the compound prepared in Preparation 6, 193mg of tetra-n-butylammonium bromide and 855mg of propargyl bromide were

added to 15ml of dichloromethane, and 5ml of 15% aquecus sodium hydroxide solution was added thereto. This mixture was stirred for 30 minutes at room temperature. The organic layer was separated, dried over anhydrous magnesium sulfate and then filtered. The filtrate was distilled under reduced pressure and the residue was purified with glass column chromatography to obtain 776mg (Yield: 92%) of the title compound.

^1H NMR ($CDCl_3$, ppm) : δ 4.92(1H, m), 4.13(2H, m), 3.76(1H, m), 3.41(1H, m), 3.25(2H, m), 3.02(1H, m), 1.50(9H, s), 1.49(9H, s)

MS (FAB, m/e) : 368(M+H)

Preparations 38 and 39

The amine compounds listed in the following Table 4 were prepared according to the same procedure as Preparation 37 except that the corresponding alkyl derivatives having R_2 structure as represented in the following Table 4 are used instead of propargyl.



Table 4. Preparations 38 and 39

Prep.	R_2	^1H NMR($CDCl_3$), δ(ppm)	FAB MS(M-H)
38	methoxymethyl	5.15-4.9(3H), 4.15(2H,m), 3.75(1H,m), 3.5-3.2(5H), 3.0(1H,m), 1.5(18H,s)	374
39	2-chloroethyl	4.9(1H,m), 4.3(2H,t), 4.1(2H,s), 3.7(3H,m), 3.6(1H,m), 3.5-3.0(3H,m), 1.45(18H,s)	391

Preparation 40

Synthesis of 4-aminomethyl-pyrrolidin-3-one t-butyloxime dihydrochloride



5ml of methanol was cooled down to 0°C and 3ml of acetyl chloride was slowly added thereto. This mixture was stirred for 10 minutes and 640mg of the compound prepared in Preparation 29, which is dissolved in 10ml of methanol, was added thereto. The reaction mixture was stirred for 20 minutes at room temperature and concentrated under reduced pressure. The residue was filtered, washed with ethylether and dried to obtain 390mg (Yield: 91%) of the title compound as a white solid.

^1H NMR (DMSO-d_6, ppm) : δ 10.0-9.6(2H, bsX2), 8.20(3H, br), 3.90(2H,dd), 3.61(1H, bs), 3.40(2H, bs),

3.12(2H, bs), 1.25(9H, s)

MS (FAB, m/e) : 186(M+H)

Preparations 41 to 50

The compounds of Preparations 41 to 50 as listed in the following Table 5 were prepared from the compounds prepared in Preparations 30 to 40 according to the same procedure as Preparation 40.



Table 5. Preparations 41 to 50

Prep.	R_2	^1H NMR($CDCl_3$), δ(ppm)	FAB MS(M+H)
41	$CH_2CH_2C{\equiv}CH$	10.1-9.8(2H,br), 8.2(3H,br), 4.3(2H,t), 4.0(2H,s), 3.7(1H,m), 3.6-3.2(3H,m), 3.0(1H,m), 2.8(1H,s), 2.6(2H,t)	182
42	isopropyl	10.1-9.8(2H,br), 8.3(3H,br), 4.4(1H,m), 3.9(2H,d), 3.7(1H,m), 3.3(2H,s), 3.1(2H,m), 1.2(6H,d)	172
43	cyclobutyl	10.2-9.8(2H,br), 8.2(3H,br), 4.8(1H,m), 4.3(2H,s), 3.7(1H,m), 3.6-3.2(3H,m), 3.0(1H,m), 1.8(2H,m), 1.7(2H,m), 1.5(1H,m), 1.45(1H,m)	184
44	cyclopentyl	10.2-9.8(2H,br), 8.2(3H,br), 4.7(1H,m), 4.3(2H,s), 3.8(1H,m), 3.3(1H,m), 3.2(3H, m), 1.8(4H,m), 1.6(2H,m), 1.5(2H,m)	198
45		10.1-9.8(2H,br), 8.3(3H,s), 4.1-3.6 (10H,m), 3.2(2H,s), 2.2-1.9(2H,m)	200
46	cyclopropyl-methyl	10.1-9.8(2H,br), 8.3(3H,s), 4.0-3.8 (4H,m), 3.65(1H,m), 3.4(2H,m), 3.1(2H,m), 1.1(1H,m), 0.5(2H,d), 0.2(2H,d)	184
47	isobutyl	10.3-9.9(2H,br), 8.4(3H,br), 3.9-3.8 (4H,m), 3.65(1H,m), 3.3(2H,s), 3.1(2H,m), 1.9(1H,m), 0.85(6H,d)	186
48	propargyl	10.0(1H,m), 8.3(2H,m), 4.8(2H,s), 4.0(2H,m), 3.7(1H,m), 3.6(1H,s) 3.4(2H,m), 3.1(2H,s)	168
49	methoxymethyl	10-9.6(2H,br), 8.2(3H,br), 5.1(2H,dd) 4.1-3.8(2H,m), 3.7(1H,m), 3.3-3.0(4H,m)	174
50	2-chloroethyl	10-9.7(2H,br), 8.2(3H,br), 4.3(2H,t), 4.0(2H,m), 3.8(2H,t), 3.7(1H,m), 3.4(2H,m), 3.2(1H,m), 3.1(2H,m)	192

Preparation 51

Synthesis of 4-(N-t-butoxycarbonyl)aminomethyl-1-(N-t-butoxycarbonyl)pyrrolidin-3-one O-methyloxime



260mg (8.23×10^{-4} mole) of the compound prepared in Preparation 5 was dissolved in the mixture of 5ml of 95% ethanol and 2.5ml of tetrahydrofuran and this solution was introduced into a reaction vessel. Then, 256mg (3.7 mole eq.) of methoxyamine hydrochloride was added thereto and 257mg (3.7 mole eq.) of sodium hydrogen carbonate($NaHCO_3$) dissolved in 2.5ml of distilled water was also added. The reaction mixture was stirred for 1 hours at 40°C under oil bath, concentrated under reduced pressure, washed successively with aqueous ammonium chloride solution and aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated to obtain 250mg (Yield: 88%) of the title compound.

^1H NMR ($CDCl_3$, ppm) : δ 4.98(1H, bs), 3.81(3H, s), 3.75-2.80(7H, m), 1.40(18H, s)

MS (FAB, m/e) : 344(M-H)

Preparations 52 and 53

The compounds listed in the following Table 6 were prepared

according to the same procedure as Preparation 51 except that phenoxyamine hydrochloride or ethoxyamine hydrochloride are used instead of methoxyamine hydrochloride.



Table 6. Preparations 52 and 53

Prep.	R_2	^1H NMR($CDCl_3$), δ(ppm)	FAB MS(M+H)
52	phenyl	7.3(5H,m), 4.97(1H,bs), 3.8-2.8(7H,m), 1.40(18H,s)	406
53	$-CH_2CH_3$	5.0(1H,bs), 3.8-2.8(7H,m), 1.42(18H,s), 1.41(18H,s), 1.38(3H,t)	358

Preparation 54

Synthesis of 4-aminomethyl-pyrrolidin-3-one O-methyloxime ditrifluoroacetate



5ml of trifluoroacetic acid was added to 250mg of the com-

pound prepared in Preparation 51, and this mixture was stirred for 20 minutes at room temperature. The reaction mixture was concentrated under reduced pressure, dissolved in the smallest amount of acetonitrile and then solidified with ethylether to obtain 220mg (Yield: 84%) of the title compound in a purified state.

^{1}H NMR (CD_3OD, ppm) : δ 4.1(2H, s), 3.96(3H, s), 3.83(1H, dd), 3.7-3.2(6H, m)

MS (FAB, m/e) : 144(M+H)

Preparations 55 to 57

The corresponding compounds of Preparations 55 to 57 were prepared from the compounds prepared in Preparations 6, 52 and 53, respectively, according to the same procedure as Preparation 54.



Table 7. Preparations 55 to 57

Prep.	R_2	^1H NMR($CDCl_3$), δ(ppm)	FAB MS(M+H)
55	-H	4.1-3.2(7H, m)	130
56	-Ph	7.2-7.4(5H, m), 4.1-3.2(7H, m)	206
57	$-CH_2CH_3$	4.2-3.1(9H, m), 1.3(3H, t)	158

Example 1

Synthesis of 7-(3-aminomethyl-3-benzyloxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid



622mg of 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid and 643mg of the compound prepared in Preparation 18 were suspended in 15ml of acetonitrile. This suspension was cooled down under ice-water bath and then 1.0ml of 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) was slowly

added thereto. The reaction mixture was stirred for 1.5 hours at room temperature and, after adding 15ml of water, was then concentrated. The concentrated suspension was filtered. The filtered solid product was washed with water and ethanol to obtain 584mg (Yield: 57%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.59(1H, s), 8.03(1H, d), 7.40(5H, m), 5.14(2H, s), 4.75(2H, s), 4.18(1H, m), 3.94(1H, m), 3.83(1H, m), 3.35(2H, m), 3.05(1H, m), 2.81(1H, m), 2.73(1H, m), 1.25-1.05(4H, m)

MS (FAB, m/e) : 466(M+H)

Examples 2 to 11

The same starting material as Example 1 was reacted with each of the compounds prepared in Preparations 19 to 23 according to the same procedure as Example 1 to prepare the respective compounds listed in the following Table 8.

Table 8. Examples 2 to 11



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (min)	Yield (%)
2		8.73(1H,s),8.05(1H,d),7.30(2H,d),6.98(2H,d),5.10(2H,s),4.61(2H,s),4.25(1H,m),3.90(1H,m),3.80(3H,s),3.70(1H,m),3.00(3H,m),1.26(2H,m),1.07(2H,m)	$CDCl_3$	496	10	75
3		8.75(1H,s),8.05(1H,d),7.45(2H,d),7.30(2H,d),5.15(2H,s),4.62(2H,s),4.25(1H,m),3.85(1H,m),3.75(1H,m),3.10(1H,m),2.98(2H,m),1.35(9H,s),1.25(2H,m),1.09(2H,m)	$CDCl_3$	522	15	76
4		8.68(1H,s),8.00(1H,d),7.35(2H,m),7.10(2H,m),5.08(2H,s),4.59(2H,s),4.20(1H,m),3.95(1H,m),3.81(1H,m),3.00(3H,m),1.23(2H,m),1.04(2H,m)	$CDCl_3$	484	15	80
5		8.59(1H,s),8.21(2H,d),8.06(1H,s),7.64(2H,d),5.29(2H,s),4.68(2H,s),4.20(1H,m),3.95(1H,m),3.85(1H,m),3.10(1H,m),2.80(2H,m),1.18(2H,m),1.10(2H,m)	DMSO	511	10	76
6		8.58(1H,s),8.05(1H,d),7.92-7.42(4H,m),5.28(2H,s),4.65(2H,s),4.20(1H,m),3.95(1H,m),3.78(1H,m),3.10(1H,m),2.80(2H,m),1.20(2H,m),1.09(2H,m)	DMSO	491	20	82

Table 8. (continued)

Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (min)	Yield (%)
7		8.74(1H,s),8.10(1H,d),6.92 (3H,m),6.10(2H,s),5.10(2H, s),4.75(2H,s),4.30(1H,m), 3.95(1H,m),3.85(1H,m),3.15 (1H,m),3.10(2H,m),1.28(2H, m),1.09(2H,m)	$CDCl_3$	510	25	79
8		8.60(1H,d),8.57(1H,s),8.52 (1H,d),8.03(1H,d),7.80(1H, d),7.41(1H,q),5.18(2H,s), 4.65(2H,s),4.17(1H,m),3.94 (1H,m),3.75(1H,m),3.30(2H, m),3.04(1H,m),2.81(1H,m), 2.73(1H,m),1.30-1.00(4H,m)	DMSO $-d_6$	467	90	70
9		8.82(1H,s),8.05(1H,d),7.51 (1H,d),7.45(1H,m),6.5(1H, s),5.02(2H,m),4.5(2H,m), 4.20(1H,m),3.95(1H,m),3.70 (1H,m),3.00(1H,m),2.80(1H, m),2.70(1H,m),1.00(4H,m)	DMSO	456	15	69
10		8.58(1H,s),8.00(1H,d),7.10 (3H,m),6.72(1H,s),4.80(2H, s),4.20(1H,m),3.95(1H,m), 3.85(1H,m),3.10(1H,m),2.95 (2H,m),1.07(4H,m)	DMSO	542	20	65
11		8.76(1H,s),8.20(1H,m),8.02 (1H,d),7.89(1H,m),7.40(1H, m),5.60(2H,s),4.78(2H,m), 4.45(1H,m),3.85(1H,m),3.70 (1H,m),3.10(2H,m),1.30(2H, m),1.15(2H,m)	DMSO	541	25	73

Example 12

Synthesis of 7-(4-aminomethyl-3-benzyloxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic

acid



530mg of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid and 584mg of the compound prepared in Preparation 8 were suspended in 15ml of acetonitrile. This suspension was cooled down under ice-water bath and then 913mg of 1,8-diacabicyclo[5.4.0]undec-7-ene(DBU) was slowly added thereto. The reaction mixture was stirred for 2 hours at 80°C and, after adding 15ml of water, was then concentrated. The concentrated suspension was filtered. The filtered solid product was washed with water and ethanol to obtain 631mg (Yield: 68%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.60(1H, s), 7.92(1H, d), 7.38(5H, m), 5.10(2H, s), 4.87(2H, s), 4.10(1H, m), 3.94(1H, m), 3.86(1H, m), 3.37(2H, m), 3.02(1H, m), 2.38(1H, m), 2.73(1H, m), 1.25-1.05(4H, m)

MS (FAB, m/e) : 465(M+H)

Examples 13 to 22

The same starting material as Example 12 was reacted with

each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 12 to prepare the respective compounds listed in the following Table 9.

Table 9. Examples 13 to 22



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
13		8.6(1H,s),7.8(1H,d),7.2(3H,d),6.9(2H,d),5.1(2H,s),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.7(3H,s),3.65(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	495	2	60
14		8.6(1H,s),7.8(1H,d),7.4(2H,d),7.3(3H,m),5.1(2H,s),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.4(9H,s),1.3-1.1(4H,m)	DMSO-d_6	521	2	65
15		8.6(1H,s),7.8(1H,d),7.4(2H,m),7.2(3H,m),5.1(2H,s),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	483	4	67
16		8.6(1H,s),8.2(2H,d),7.8(1H,d),7.6(2H,d),7.2(1H,d),5.3(2H,s),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	510	3	58

Table 9. (continued)

Exemp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
17		8.6(1H,s),7.9-7.4(5H,m),7.2(1H,d),5.3(2H,s),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	490	4	55
18		8.6(1H,s),7.8(1H,d),7.2(1H,d),6.9(3H,m),6.1(2H,s),5.1(2H,s),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	509	4	71
19		8.6(3H,m),7.8(2H,m),7.4(1H,q),7.2(1H,d),5.2(2H,s),4.4(1H,m),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	466	4	53
20		8.6(1H,s),7.8(1H,d),7.5(2H,m),7.2(1H,d),6.5(1H,m),5.0(2H,m),4.4(1H,m),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	455	4	60
21		8.6(1H,s),7.8(1H,d),7.2(1H,d),7.1(3H,m),6.7(1H,s),4.4(1H,m),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	541	4	50
22		8.6(1H,s),8.2(1H,m),7.9-7.8(2H,m),7.4(1H,m),7.2(1H,d),5.6(2H,s),4.4(1H,m),3.9(1H,m),3.8(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	540	4	70

Example 23

Synthesis of 7-(4-aminomethyl-3-benzyloxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid



566mg of 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and 584mg of the compound prepared in Preparation 8 were suspended in 15ml of acetonitrile. This suspension was cooled down under ice-water bath and then 913mg of 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) was slowly added thereto. The reaction mixture was stirred for 2 hours at 80°C and, after adding 10ml of water, was then concentrated. The concentrated suspension was filtered. The filtered solid product was washed with water and ethanol to obtain 704mg (Yield: 73%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.64(1H, s), 7.99(1H, d), 7.41(5H, m), 5.10(2H, s), 4.73(2H, s), 4.18(1H, m), 3.92(1H, m), 3.86(1H, m), 3.37(2H, m), 3.02(1H, m), 2.83(1H, m), 2.73(1H, m), 1.25-1.05(4H, m)

MS (FAB, m/e) : 483(M+H)

Examples 24 to 33

The same starting material as Example 23 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 23 to prepare the respective compounds listed in the following Table 10.

Table 10. Examples 24 to 33



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
24		8.6(1H,s),7.7(1H,d),7.2(2H,d),6.9(2H,d),5.1(2H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),3.7(3H,s),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	513	2	75
25		8.6(1H,s),7.7(1H,d),7.5(2H,m),7.1(2H,m),5.1(2H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.4(9H,s),1.15(4H,m)	DMSO-d_6	539	4	70
26		8.6(1H,s),7.7(1H,d),7.3(2H,m),7.1(2H,m),5.1(2H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	501	4	80
27		8.6(1H,s),8.2(2H,d),7.7(1H,d),7.6(2H,d),5.3(2H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	528	3	68
28		8.6(1H,s),7.9-7.4(5H,m),5.3(2H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	508	2	70

Table 10. (continued)

Exemp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
29		8.6(1H,s),7.7(1H,d),7.0(3H,m),6.1(2H,s),5.1(2H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	527	3	69
30		8.6(3H,m),7.8(1H,d),7.7(1H,d),7.4(1H,q),5.3(2H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	484	3	58
31		8.6(1H,s),7.7(1H,d),7.5(2H,m),6.5(1H,m),5.0(2H,m),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	473	3	70
32		8.6(1H,s),7.7(1H,d),7.1(3H,m),6.6(1H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	559	4	59
33		8.6(1H,s),8.3(1H,m),7.9(1H,m),7.7(1H,d),7.4(1H,m),5.6(2H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	558	4	60

Example 34

Synthesis of 7-(4-aminomethyl-3-benzyloxyimino-pyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid



598mg of 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid and 584mg of the compound prepared in Preparation 8 were suspended in 15ml of acetonitrile and then 913mg of 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) was slowly added thereto. The reaction mixture was stirred for 3 hours at 80°C and, after adding 15ml of water, was then concentrated. The concentrated suspension was filtered. The filtered solid product was washed with water and ethyl ether to obtain 510mg (Yield: 52%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.78(1H, s), 7.91(1H, d), 7.41(5H, m), 5.16(2H, s), 4.74(2H, s), 4.16(1H, m), 3.90(1H, m), 3.85(1H, m), 3.35(2H, m), 3.02(1H, m), 2.82(1H, m), 2.75(1H, m), 1.30-1.10(4H, m)

MS (FAB, m/e) : 499(M+H)

Examples 35 to 44

The same starting material as Example 34 was reacted with each of the compounds prepared in Preparations 19 to 28 according

to the same procedure as Example 34 to prepare the respective compounds listed in the following Table 11.

Table 11. Examples 35 to 44



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
35		8.7(1H,s),7.9(1H,d),7.3(2H,d),7.0(2H,d),5.1(2H,s),4.4(2H,s),4.3(1H,m),3.8(1H,m),3.7(3H,s),3.0(1H,m),2.9-2.6(2H,s),1.2-0.9(4H,m)	DMSO-d_6	529	3	63
36		8.7(1H,s),7.9(1H,d),7.5(2H,d),7.3(2H,d),5.2(2H,s),4.4(2H,s),4.3(1H,m),3.8(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.4(9H,s),1.2-0.9(4H,m)	DMSO-d_6	555	3	73
37		8.7(1H,s),7.9(1H,d),7.4(2H,m),7.1(2H,m),5.1(2H,s),4.4(2H,s),4.3(1H,m),3.8(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.2-0.9(4H,m)	DMSO-d_6	517	2	80
38		8.7(1H,s),8.3(2H,d),7.9(1H,d),7.7(2H,d),5.4(2H,s),4.4(2H,s),4.3(1H,m),3.8(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.2-0.9(4H,m)	DMSO-d_6	544	4	63

Table 11. (continued)

Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
39		8.7(1H,s),7.9-7.4(5H,m),5.3 (2H,s),4.4(2H,s),4.3(1H,m), 3.8(1H,m),3.0(1H,m),2.9-2.7 (2H,m),1.2-0.9(4H,m)	DMSO -d_6	524	4	70
40		8.7(1H,s),7.9(1H,d),7.0(3H, m),6.1(2H,s),5.1(2H,s),4.4 (2H,s),4.3(1H,m),3.8(1H,m), 3.0(1H,m),2.9-2.7(2H,m), 1.2-0.9(4H,m)	DMSO -d_6	543	2	67
41		8.7(1H,s),7.9(1H,d),8.6(2H, m),7.8(1H,d),7.4(1H,q),5.2 (2H,s),4.4(2H,s),4.3(1H,m), 3.8(1H,m),3.0(1H,m),2.9-2.7 (2H,m),1.2-0.9(4H,m)	DMSO -d_6	500	4	60
42		8.7(1H,s),7.9(1H,d),7.5(2H, m),6.5(1H,m),5.0(2H,m),4.4 (2H,s),4.3(1H,m),3.8(1H,m), 3.0(1H,m),2.9-2.7(2H,m), 1.2-0.9(4H,m)	DMSO -d_6	489	2	62
43		8.7(1H,s),7.9(1H,d),7.1(3H, m),6.7(1H,s),4.4(2H,s),4.3 (1H,m),3.8(1H,m),3.0(1H,m), 2.9-2.6(2H,m),1.2-0.9(4H,m)	DMSO -d_6	575	4	60
44		8.7(1H,s),8.2(1H,m),7.9(2H, m),7.4(1H,m),5.6(2H,s),4.4 (2H,s),4.3(1H,m),3.8(1H,m), 3.0(1H,m),2.9-2.7(2H,m), 1.2-0.9(4H,m)	DMSO -d_6	574	4	76

Example 45

Synthesis of 7-(4-aminomethyl-3-benzyloxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid



590mg of 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid and 584mg of the compound prepared in Preparation 8 were suspended in 15ml of acetonitrile and then 913mg of 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) was slowly added thereto. The reaction mixture was stirred for 2 hours at 80°C and, after adding 15ml of water, was then stirred for 30 minutes at room temperature and filtered. The filtered solid product was washed with water and ethyl ether to obtain 465mg (Yield: 47%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.61(1H, s), 7.99(1H, d), 7.40(5H, m), 5.15(2H, s), 4.74(2H, s), 4.17(1H, m), 3.95(1H, m), 3.83(1H, m), 3.60(3H, s), 3.35(2H, m), 3.02(1H, m), 2.80(1H, m), 2.71(1H, m), 1.30-1.10(4H, m)

MS (FAB, m/e) : 495(M+H)

Examples 46 to 55

The same starting material as Example 45 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 45 to prepare the respective

compounds listed in the following Table 12.

Table 12. Examples 46 to 55



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
46		8.8(1H,s),7.8(1H,d),7.4(2H,d),7.1(2H,d),5.2(2H,s),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.8(3H,s),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	525	17	38
47		8.8(1H,s),7.8(1H,d),7.6(2H,d),7.4(2H,d),5.3(2H,s),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.5(9H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	551	17	34
48		8.8(1H,s),7.8(1H,d),7.5(2H,m),7.2(2H,m),5.2(2H,s),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	513	17	40
49		8.8(1H,s),8.3(2H,d),7.8(1H,d),7.7(2H,d),5.4(2H,s),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	540	17	37

Table 11. (continued)

Examp. No.	R	^1H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
50		8.8(1H,s),8.0-7.5(5H,m),5.4(2H,s),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	520	17	42
51		8.8(1H,s),7.8(1H,d),7.0(3H,m),6.2(2H,s),5.2(2H,s),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	539	17	44
52		8.8(1H,s),8.6(2H,m),7.9(1H,d),7.8(1H,d),7.4(1H,q),5.3(2H,s),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	496	17	30
53		8.8(1H,s),7.8(1H,d),7.6(2H,m),6.5(1H,m),5.1(2H,m),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	485	17	29
54		8.8(1H,s),7.8(1H,d),7.2(3H,m),6.8(1H,s),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	571	20	27
55		8.8(1H,s),8.3(1H,m),8.0(1H,m),7.8(1H,d),7.5(1H,m),5.7(2H,s),4.6(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),1.3(2H,m),0.95(2H,m)	DMSO-d_6	570	17	42

Example 56

Synthesis of 5-amino-7-(4-aminomethyl-3-benzyloxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid



448mg of 5-amino-1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid and 438mg of the compound prepared in Preparation 8 were suspended in 15ml of acetonitrile and then 685mg of 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) was slowly added thereto. The reaction mixture was heated for 6 hours at 80°C and 10ml of water was added thereto. This suspension was filtered. The filtered solid product was washed with water, acetonitrile and ethyl ether to obtain 395mg (Yield: 53%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.62(1H, s), 7.92(1H, d), 7.40(5H, m), 6.10(2H, bs), 5.13(2H, s), 4.73(2H, s), 4.15(1H, m), 3.95(1H, m), 3.82(1H, m), 3.35(2H, m), 3.01(1H, m), 2.80(1H, m), 2.73(1H, m), 1.25-1.05(4H, m)

MS (FAB, m/e) : 498(M+H)

Examples 57 to 66

The same starting material as Example 56 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 56 to prepare the respective compounds listed in the following Table 13.

Table 13. Examples 57 to 66



Examp. No.	R	^1H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
57		8.4(1H,s),7.4(2H,bs),7.2(2H,d),7.0(2H,d),5.1(2H,s),4.6(2H,m),4.2(1H,m),3.9(1H,m),3.8(3H,s),3.7(1H,m),3.0(1H,m),2.8-2.6(2H,m),1.1(4H,s)	DMSO $-d_6$	523	10	59
58		8.4(1H,s),7.5(2H,d),7.4(2H,bs),7.3(2H,d),5.2(2H,s),4.6(2H,m),4.2(1H,m),3.9(1H,m),3.7(1H,m),3.0(1H,m),2.8-2.6(2H,m),1.4(9H,s),1.1(4H,s)	DMSO $-d_6$	554	17	67
59		8.4(1H,s),7.4(4H,m),7.1(2H,m),5.1(2H,s),4.6(2H,m),4.2(1H,m),3.9(1H,m),3.7(1H,m),3.0(1H,m),2.8-2.6(2H,m),1.1(4H,s)	DMSO $-d_6$	516	17	55
60		8.4(1H,s),8.2(2H,d),7.6(2H,d),7.4(2H,bs),5.3(2H,s),4.6(2H,m),4.2(1H,m),3.9(1H,m),3.7(1H,m),3.0(1H,m),2.8-2.6(2H,m),1.1(4H,s)	DMSO $-d_6$	543	17	56
61		8.4(1H,s),7.9-7.4(6H,m),5.3(2H,s),4.6(2H,m),4.2(1H,m),3.9(1H,m),3.7(1H,m),3.0(1H,m),2.8-2.6(2H,m),1.1(4H,s)	DMSO -d6	523	18	62

Table 13. (continued)

Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
62		8.4(1H,s),7.3(2H,bs),7.0 (3H,m),6.2(2H,s),5.2(2H,s), 4.6(2H,m),4.2(1H,m),3.9(1H, m),3.7(1H,m),3.0(1H,m),2.8-2.6(2H,m),1.1(4H,s)	DMSO-d_6	542	18	65
63		8.5(3H,m),7.6(1H,d),7.4(1H, q),7.3(2H,bs),5.3(2H,s),4.6 (2H,m),4.2(1H,m),3.9(1H,m), 3.7(1H,m),3.0(1H,m),2.8-2.6 (2H,m),1.1(4H,s)	DMSO-d_6	499	17	52
64		8.4(1H,s),7.5-7.4(4H,m),6.5 (1H,m),5.0(2H,m),4.6(2H,m), 4.2(1H,m),3.9(1H,m),3.7(1H, m),3.0(1H,m),2.8-2.6(2H,m), 1.1(4H,s)	DMSO-d_6	488	18	49
65		8.4(1H,s),7.4(2H,bs),7.1 (3H,m),6.7(1H,s),4.6(2H,m), 4.2(1H,m),3.9(1H,m),3.7(1H, m),3.0(1H,m),2.8-2.6(2H), 1.1(4H,s)	DMSO-d_6	574	18	43
66		8.4(1H,s),8.2(1H,m),7.9(1H, m),7.4(3H,m),5.6(2H,s),4.6 (2H,m),4.2(1H,m),3.9(1H,m), 3.7(1H,m),3.0(1H,m),2.8-2.6 (2H,m),1.1(4H,s)	DMSO-d_6	573	17	65

Example 67

Synthesis of 7-(4-aminomethyl-3-benzyloxyimino-pyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid



800mg of 7-chloro-1(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid and 438mg of the compound prepared in Preparation 6 were suspended in 15ml of acetonitrile and then 910mg of 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) was slowly added thereto. The reaction mixture was stirred for one hour at room temperature, and after adding 15ml of water, was then stirred for further 30 minutes and filtered. The filtered solid product was washed with water and acetonitrile to obtain 524mg (Yield: 65%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.82(1H, s), 8.21(1H, d), 7.85(1H, m), 7.56(1H, m), 7.40(6H, m), 5.16(2H, s), 4.76(2H, s), 4.18(1H, m), 3.94(1H, m), 3.81(1H, m), 3.34(2H, m), 3.04(1H, m), 2.82(1H, m), 2.73(1H, m), 1.30-1.00(4H, m)

MS (FAB, m/e) : 538(M+H)

Examples 68 to 77

The same starting material as Example 67 was reacted with each of the compounds prepared in Preparations 19 to 28 according

to the same procedure as Example 67 to prepare the respective compounds listed in the following Table 14.

Table 14. Examples 68 to 77



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (min)	Yield (%)
68		8.9(1H,s),8.1(1H,d),7.8(1H,m),7.6(1H,dd),7.3(3H,m),7.1(2H,d),5.2(2H,s),4.3(2H,s),4.0(1H,m),3.9(1H,m),3.8(3H,s),3.0(1H,m),2.8-2.6(2H,m)	DMSO-d_6	568	20	78
69		8.9(1H,s),8.1(1H,d),7.8(1H,m),7.6(2H,m),7.3(2H,m),5.2(2H,s),4.3(2H,s),3.9(1H,m),3.0(1H,m),2.8-2.6(2H,m),1.5(9H,s)	DMSO-d_6	594	10	80
70		8.9(1H,s),8.1(1H,d),7.8(1H,m),7.6(1H,dd),7.4(2H,m),7.3(1H,dd),7.1(2H,m),5.1(2H,s),4.3(2H,s),4.0(1H,m),3.9(1H,m),3.0(1H,m),2.8-2.6(2H,m)	DMSO-d_6	556	15	81
71		8.9(1H,s),8.3(2H,d),8.1(1H,d),7.8(1H,m),7.7(2H,d),7.6(1H,dd),7.3(1H,m),5.3(2H,s),4.3(2H,s),4.0(1H,m),3.9(1H,m),3.0(1H,m),2.8-2.6(2H,m)	DMSO-d_6	583	15	75

Table 14. (continued)

Exmp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (min)	Yield (%)
72		8.8(1H,s),8.1(1H,d),7.9-7.4 (6H,m),7.3(1H,dd),5.3(2H, s),4.3(2H,s),4.0(1H,m),3.9 (1H,m),3.0(1H,m),2.8-2.6 (2H,m)	DMSO -d_6	563	15	80
73		8.8(1H,s),8.1(1H,d),7.8(1H, m),7.6(1H,dd),7.3(1H,dd), 7.0(3H,m),6.2(2H,s),5.1(2H, s),4.3(2H,s),4.0(1H,m),3.9 (1H,m),3.0(1H,m),2.8-2.6 (2H,m)	DMSO -d_6	582	15	87
74		8.8(1H,s),8.6(1H,s),8.5(1H, q),7.8(2H,m),7.6(1H,dd),7.4 (1H,q),7.3(1H,dd),5.2(2H, s),4.3(2H,s),4.0(1H,m),3.9 (1H,m),3.0(1H,m),2.8-2.6 (2H,m)	DMSO -d_6	539	15	70
75		8.8(1H,s),8.1(1H,d),7.8(1H, m),7.6(1H,dd),7.5(1H,d), 7.45(1H,dd),6.6(1H,m),5.0 (2H,m),4.3(2H,s),4.0(1H,m), 3.9(1H,m),3.0(1H,m), 2.8-2.6(2H,m)	DMSO -d_6	528	10	69
76		8.8(1H,s),8.1(1H,d),7.8(1H, m),7.6(1H,dd),7.3(1H,dd), 7.1(3H,m),6.7(1H,s),4.3(2H, s),4.0(1H,m),3.9(1H,m),3.0 (1H,m),2.8-2.6(2H,m)	DMSO -d_6	614	20	89
77		8.8(1H,s),8.2(1H,m),8.1(1H, d),8.0(1H,m),7.8(1H,d),7.6 (1H,dd),7.4(1H,m),7.3(1H, dd),5.6(2H,s),4.3(2H,s),4.0 (1H,m),3.9(1H,m),3.0(1H,m), 2.8-2.6(2H,m)	DMSO -d_6	613	10	82

Example 78

Synthesis of 7-(4-aminomethyl-3-benzyloxyiminopyrrolidin-1-yl)-1-ethyl-6,8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid



353mg of 1-ethyl-6,7,8-trifluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid and 380mg of the compound prepared in Preparation 8 were suspended in 15ml of acetonitrile and then 593mg of 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) was slowly added thereto. The reaction mixture was stirred for 2.5 hours at 80°C, and after adding 15ml of water, was then stirred for further 30 minutes under cold water bath and filtered. The filtered solid product was washed with water, acetonitrile and ethyl ether to obtain 391mg (Yield: 64%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.8(1H, s), 7.8(1H, d), 7.40(5H, m), 5.10(2H,s), 4.6(2H, q), 4.4(2H, dd), 4.0(1H, m), 3.7(1H, m), 3.1(1H, m), 2.8(2H, ddd), 1.46(3H, t)

MS (FAB, m/e) : 471(M+H)

Examples 79 to 83

The same starting material as Example 78 was reacted with

each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 78 to prepare the respective compounds listed in the following Table 15.

Table 15. Examples 79 to 83



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
79		8.8(1H,s),7.8(1H,d),7.4(2H,d),7.1(2H,d),5.0(2H,s),4.5(2H,q),4.4(2H,s),4.2(1H,m),3.9(1H,m),3.7(3H,s),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t)	DMSO-d_6	501	4	73
80		8.8(1H,s),7.8(1H,d),7.4(2H,d),7.2(2H,d),5.1(2H,s),4.5(2H,q),4.4(2H,s),4.1(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t),1.4(9H,s)	DMSO-d_6	527	2.5	77
81		8.8(1H,s),7.8(1H,d),7.3(2H,m),7.0(2H,m),5.0(2H,s),4.5(2H,q),4.4(2H,s),4.2(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t)	DMSO-d_6	489	3	80
82		8.8(1H,s),8.3(2H,d),7.8(1H,d),7.7(2H,d),5.3(2H,s),4.5(2H,q),4.4(2H,s),4.2(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t)	DMSO-d_6	516	3	75

Table 15. (continued)

Exmp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
83		8.8(1H,s),7.9-7.4(5H,m),5.3(2H,s),4.5(2H,q),4.4(2H,s),4.2(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t)	DMSO-d_6	496	3	80
84		8.8(1H,s),7.8(1H,d),6.8(3H,m),6.0(2H,s),5.0(2H,s),4.5(2H,q),4.4(2H,s),4.2(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t)	DMSO-d_6	515	4	69
85		8.8(1H,s),8.6(2H,m),7.8(2H,m),7.4(1H,q),5.3(2H,s),4.5(2H,q),4.4(2H,s),4.2(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t)	DMSO-d_6	471	2	70
86		8.8(1H,s),7.8(1H,d),7.5(2H,m),6.5(1H,m),5.0(2H,m),4.5(2H,q),4.4(2H,s),4.2(1H,m),2.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t)	DMSO-d_6	461	2	67
87		8.8(1H,s),7.8(1H,d),7.1(3H,m),6.7(1H,s),4.5(2H,q),4.4(2H,s),4.2(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t)	DMSO-d_6	547	3	63
88		8.8(1H,s),8.2(1H,m),7.9(1H,m),7.8(1H,d),7.4(1H,m),5.6(2H,s),4.5(2H,q),4.4(2H,s),4.2(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.5(3H,t)	DMSO-d_6	546	4	70

Example 89

Synthesis of 7-(4-aminomethyl-3-t-butyloxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carb-

boxylic acid



141mg (0.5 mmole) of 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid and 140mg (0.55 mmole) of 4-aminomethyl-pyrrolidin-3-one t-butyloxime dihydrochloride were thoroughly suspended in 2.5ml of acetonitrile. Then, 200mg (1.5 mmole) of 1,8-diazabicyclo[5.4.0]undec-7-ene was slowly added dropwise thereto. The reaction mixture was stirred for 30 minutes at room temperature, and after adding 1ml of water, was then vigorously stirred for 10 minutes and filtered. The filtered solid product was successively washed with acetonitrile-water (4:1 v/v, 2ml) and acetonitrile (2ml×2) and then with ether and dried to obtain 130mg (Yield: 61%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.6(1H, s), 8.1(1H, d), 7.6 (2H, s), 4.2(1H, dd), 3.9(1H, dd), 3.7-3.1(3H, m), 3.1(1H, dd), 2.9-2.7(3H, m), 1.3(9H, s), 1.2(2H, m), 1.1 (2H, m)

FAB MS (POS) : 408[M+H]$^+$

Example 60

Synthesis of 7-(3-aminomethyl-4-t-butyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-1-oxo-1,4-dihydroquinoline-3-carboxylic acid



111mg (0.5 mmole) of 1-cyclopropyl-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and 140mg (0.55 mmole) of 3-aminomethyl-4-t-butyloxyiminopyrrolidine dihydrochloride were refluxed for 2.5 hours under heating according to the same manner as Example 33 and cooled down to room temperature. Then, the resulting product was then separated and purified with preparative HPLC to obtain 151mg (Yield: 67%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.8(1H, s), 7.8(1H, d), 4.5(2H, s), 4.3(1H, m), 3.9(1H, m), 3.8(1H, m), 2.9(1H, m), 2.3-2.7(2H, m), 1.3(9H, s), 1.15(4H, s)

FAB MS(POS) : 449$[M-H]^+$

Example 21

Synthesis of 8-chloro-1-cyclopropyl-6-fluoro-7-(3-aminomethyl-4-t-butyloxyiminopyrrolidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid



150mg (0.5 mmole) of 8-chloro-1-cyclopropyl-6,7-difluoro-1-oxo-1,4-dihydroquinoline-3-carboxylic acid was reacted according to the same manner as Example 90. Then, the reaction solution was concentrated and the residue was purified with preparative HPLC to obtain 148mg (Yield: 64%) of the title compound.

^{1}H NMR (CH$_3$OD-d$_4$, ppm) : δ 8.7(1H, s), 7.9(1H, d), 4.4(2H, s), 4.3(1H, m), 3.8(1H, m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 1.3(9H, s), 1.2-0.9(4H, m)

FAB MS(POS) : $[M+H]^+$ = 465

Example 96

1-cyclopropyl-6-fluoro-1-oxo-1,4-dihydroquinoline-3-carboxylic acid



100mg (0.5 mmole) of 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid was refluxed for 3.5 hours under heating according to the same manner as Example 39. Then, the resulting residue was subjected to preparative HPLC to obtain 129mg (Yield: 60%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.4(2H, s), 3.9(1H, m), 3.8(1H, m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 1.4(9H, s), 1.3-1.1(4H, m)

FAB MS(POS) : $[M+H]^+$ = 431

Example 60

(Carboxylic acid of 5-amino-7-(3-aminocarbonyl-1-t-butyloxyiminopyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydroquinoline-3-carboxylic acid



110mg (0.3 mmole) of 5-amino-1-cyclopropyl-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid was refluxed for 3 hours under heating according to the same manner as Example 39. Then, the resulting residue was purified with preparative HPLC to obtain 151mg (Yield: 65%) of the title compound.

^1H NMR (DMSO-d_6, ppm) : δ 8.6(1H, s), 7.5(2H, br), 4.3(2H, s), 4.0-3.8(3H, m), 3.3(1H, m), 2.8-2.6(3H, m), 1.3(9H, s), 1.1(4H, m)

FAB MS(POS) : $[M+H]^+$ = 464

Example 94

Synthesis of 7-(3-aminomethyl-4-t-butyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid



148mg (0.5 mmole) of 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid was refluxed for 10 hours under heating according to the same manner as Example 89. Then, the resulting residue was purified with preparative HPLC to obtain 92mg (Yield: 40%) of the title compound.

^1H NMR (DMSO-d_6, ppm) : δ 8.9(1H, s), 7.8(1H, d), 4.5(2H, s), 4.3(1H, m), 4.1(1H, m), 3.9(1H, m), 3.0(1H, m), 2.8-2.7(2H, m), 2.7(3H, s), 1.3(9H, s), 1.25(2H, m), 0.9(2H, s)

FAB MS(POS) : $[M+H]^+$ = 461

Example 95

Synthesis of 7-(3-aminomethyl-4-t-butyloxyiminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid



168mg (0.5 mmole) of 6,7-difluoro-1-(2,4-difluorophenyl)-4-oxo-1,4-dihydro-naphthyridine-3-carboxylic acid and 143mg (0.55 mmole) of 3-aminomethyl-4-t-butyloxyiminopyrrolidine dihydrochloride were suspended in 3ml of dry acetonitrile. Then, 230mg (1.5 mmole) of 1,8-diazabicyclo[5.4.0]undec-7-ene was added thereto, and the reaction mixture was stirred for 15 minutes at room temperature and then treated according to the same manner as Example 89 to obtain 203mg (Yield: 81%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.9(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H, dd), 4.3(2H, s), 4.0(1H, m), 3.9(1H, m), 3.0(1H, m), 2.8-2.6(2H, m), 1.3(9H, s)

FAB MS(POS) : $[M+H]^+$ = 504

Example 96

Synthesis of 7-(3-aminomethyl-4-t-butyloxyiminopyrrolidin-1-yl)-

6,8-difluoro-1-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid



136mg (0.5 mmole) of 1-ethyl-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid was refluxed for 5 hours under heating according to the same manner as Example 89. Then, the resulting residue was purified with preparative HPLC to obtain 170mg (Yield: 70%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.8(1H, s), 7.8(1H, d), 4.5(2H, q), 4.4(2H, s), 4.2(1H, m), 3.9(1H, m), 3.1(1H, m), 2.9-2.7(2H, m), 1.45(3H, t), 1.3(9H, s)

FAB MS(POS) : $[M+H]^+$ = 437

Examples 97 to 176

The amine compounds prepared in Preparations 41 to 50 were treated according to the same procedure as Examples 89 to 96 to prepare the respective compounds 97 to 176 of which NMR and MS data are listed in the following Tables 16 to 23.

Table 16. Examples 97 to 106



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (min)	Yield (%)
97		8.6(1H,s),8.0(1H,d),4.7(1H,m),4.6(2H,s),4.2(1H,m),3.9(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.2-1.0(4H,m),0.9(6H,d)	DMSO-d_6	418	10	73
98		8.6(1H,s),8.05(1H,d),4.8(1H,m),4.7(2H,s),4.2(1H,m),4.0(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.2(2H,m),2.1(2H,m),1.7(1H,m),1.5(1H,m),1.2-1.0(4H,m)	DMSO-d_6	430	10	65
99		8.6(1H,s),8.0(1H,d),4.7(1H,m),4.5(2H,s),4.2(1H,m),3.9(1H,m),3.7(1H,m),3.1(1H,m),2.9-2.8(2H,m),1.7(4H,s),1.6(2H,m),1.5(2H,m),1.2-1.0(4H,m)	DMSO-d_6	444	50	77
100		8.6(1H,s),8.0(1H,d),4.8(1H,m),4.6(2H,s),4.2(1H,m),3.9(1H,m),3.8-3.6(5H,m),3.1(1H,m),2.9-2.7(2H,m),2.3-1.9(2H,m),1.2-1.0(4H,m)	DMSO-d_6	446	30	61
101		8.65(1H,s),8.05(1H,d),4.6(2H,s),4.25(1H,m),3.9(1H,m),3.85(2H,dd),3.75(1H,m),3.1(1H,m),3.0-2.8(2H,m),1.3-1.0(5H,m),0.5(2H,m),0.3(2H,m)	DMSO-d_6	430	30	84

Table 16. (continued)

Exemp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (min)	Yield (%)
102		8.6(1H,s),8.0(1H,d),4.6(2H,s),4.2(1H,m),3.95(1H,m),3.8(2H,d),3.7(1H,m),3.05(1H,m),2.9-2.7(2H,m),1.9(1H,m),1.2-1.0(4H,m),0.9(6H,d)	DMSO-d_6	402	15	80
103		8.60(1H,s),8.05(1H,d),4.74(2H,s),4.60(2H,s),4.21(1H,m),3.97(1H,m),3.75(1H,m),3.50(1H,s),3.35(2H,s),3.08(1H,m),2.90-2.70(2H,m),1.30-1.05(4H,m)	DMSO-d_6	414	90	63
104		8.6(1H,s),8.0(1H,d),4.6(2H,s),4.2(1H,m),4.1(2H,t),3.9(1H,m),3.7(1H,m),3.1(1H,m),2.9-2.7(2H,m),2.8(1H,s),2.5(2H,t),1.2-1.0(4H,m)	DMSO-d_6	428	15	60
105		8.6(1H,s),8.0(1H,d),4.6(2H,s),4.2(1H,m),3.9(1H,m),3.7(1H,m),3.4(2H,s),3.3(3H,s),3.0(1H,m),2.8-2.6(2H,m),1.2-1.0(4H,m)	DMSO-d_6	420	20	50
106		8.6(1H,s),8.05(1H,d),4.6(2H,s),4.3(2H,t),4.2(1H,m),3.9(1H,m),3.8(2H,t),3.7(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.2-1.0(4H,m)	DMSO-d_6	438	10	50

Table 17. Examples 107 to 116



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
107		8.8(1H,s),7.8(1H,d),4.7(1H,m),4.5(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,s),0.9(6H,d)	DMSO-d_6	435	2	69
108		8.8(1H,s),7.8(1H,d),4.8(1H,m),4.4(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),2.2(2H,m),2.1(2H,m),1.7(1H,m),1.5(1H,m),1.15(4H,s)	DMSO-d_6	447	2	61
109		8.8(1H,s),7.8(1H,d),4.7(1H,m),4.5(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),2.9(1H,m),2.8-2.7(2H,m),1.7(4H,s),1.6(2H,m),1.5(2H,m),1.15(2H,m),1.0(2H,m)	DMSO-d_6	461	2	63
110		8.8(1H,s),7.8(1H,d),4.8(1H,m),4.5(2H,s),4.1(1H,m),3.9(1H,m),3.8-3.6(4H,m),3.1(1H,m),2.8-2.7(2H,m),2.3-1.9(2H,m),1.2-1.0(4H,s)	DMSO-d_6	463	2	54
111		8.8(1H,s),7.8(1H,d),4.5(2H,s),4.1(1H,m),3.9(1H,m),3.8(2H,dd),3.75(1H,m),3.1(1H,m),2.8-2.7(2H,m),1.15(4H,m),1.05(1H,m),0.5(2H,m),0.3(2H,m)	DMSO-d_6	447	2	59

Table 17. (continued)

Comp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
112		8.8(1H,s),7.8(1H,d),4.5(2H,s),4.1(1H,m),3.9(1H,m),3.8(2H,d),3.75(1H,m),3.0(1H,m),2.8-2.7(2H,m),1.9(1H,m),1.2-1.0(4H,m),0.9(6H,d)	DMSO-d_6	449	2	64
113		8.8(1H,s),7.8(1H,d),4.62(2H,s),4.3(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),3.5(1H,s),2.9(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	431	4	55
114		8.8(1H,s),7.8(1H,d),4.5(2H,s),4.1(1H,m),4.0(2H,t),3.9(1H,m),3.8(1H,m),3.1(1H,m),2.8-2.7(2H,m),2.7(1H,s),2.5(2H,t),1.2(4H,m)	DMSO-d_6	445	2	65
115		8.8(1H,s),7.8(1H,d),4.5(2H,s),4.1(1H,m),3.9(1H,m),3.8(1H,m),3.3(2H,s),3.1(3H,s),3.0(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	437	1.5	47
116		8.8(1H,s),7.8(1H,d),4.5(2H,s),4.3(2H,t),4.1(1H,m),3.9(1H,m),3.8(2H,t),3.75(1H,m),3.0(1H,m),2.8-2.7(2H,m),1.15(4H,m)	DMSO-d_6	455	1.5	53

Table 13. Examples 117 to 126



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
117		8.8(1H,s),7.9(1H,d),4.7(1H,m),4.4(2H,s),4.3(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.8-0.9(4H,m),0.9(6H,d)	DMSO-d_6	451	2.5	63
118		8.8(1H,s),7.9(1H,d),4.7(1H,m),4.4(2H,s),4.3(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.2(2H,m),2.1(2H,m),1.7(1H,m),1.5(1H,m),1.12-0.9(4H,m)	DMSO-d_6	463	2	61
119		8.8(1H,s),7.9(1H,d),4.7(1H,m),4.4(2H,s),4.3(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.7(4H,s),1.6(2H,m),1.5(2H,m),1.2-0.9(4H,m)	DMSO-d_6	477	2	55
120		8.8(1H,s),7.9(1H,d),4.8(1H,m),4.4(2H,s),4.3(1H,m),3.8-3.6(6H,m),3.0(1H,m),2.9-2.7(2H,m),2.3-1.9(2H,m),1.2-0.9(4H,m)	DMSO-d_6	479	2.5	49
121		8.9(1H,s),7.9(1H,d),4.4(2H,s),4.3(1H,m),3.8-3.7(4H,m),3.0(1H,m),2.9-2.7(2H,m),1.2-0.9(5H,m),0.5(2H,m),0.3(2H,m)	DMSO-d_6	463	2	52

Table 18. (continued)

Exmp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
122		8.8(1H,s),7.9(1H,d),4.4(2H,s),4.3(1H,m),3.8-3.7(4H,m),3.0(1H,m),2.9-2.7(2H,m),1.9(1H,m),1.2-0.9(4H,m),0.9(6H,d)	DMSO-d_6	465	2	60
123		8.8(1H,s),7.9(1H,d),4.61(2H,s),4.4(2H,s),4.3(1H,m),3.8(1H,m),3.5(1H,s),3.0(1H,m),2.9-2.7(2H,m),1.2-0.9(4H,m)	DMSO-d_6	447	2	62
124		8.8(1H,s),7.9(1H,d),4.4(2H,s),4.3(1H,m),4.1(2H,t),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.8(1H,s),2.5(2H,t),1.2-0.9(4H,m)	DMSO-d_6	461	2.5	57
125		8.8(1H,s),7.9(1H,d),4.4(2H,s),4.3(1H,m),3.8(1H,m),3.7(1H,m),3.3(2H,s),3.1(3H,s),3.0(1H,m),2.9-2.7(2H,m),1.2-0.9(4H,m)	DMSO-d_6	453	1.5	51
126		8.8(1H,s),7.9(1H,d),4.4(2H,s),4.3(3H,m),3.8-3.7(4H,m),3.0(1H,m),2.9-2.7(2H,m),1.2-0.9(4H,m)	DMSO-d_6	471	2	64

Table 19. Examples 127 to 136



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
127		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.6(1H,m),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m),0.9(6H,d)	DMSO-d_6	417	3	55
128		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.7(1H,m),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.2(2H,m),2.1(2H,m),1.7(1H,m),1.5(2H,m),1.3-1.1(4H,m)	DMSO-d_6	429	3	52
129		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.7(1H,m),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.7(4H,s),1.6(2H,m),1.5(2H,m),1.3-1.1(4H,m)	DMSO-d_6	443	3	59
130		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.8(1H,m),4.4(2H,s),3.9(1H,m),3.8-3.6(6H,m),3.0(1H,m),2.9-2.7(2H,m),2.3-1.9(2H,m),1.3-1.1(4H,m)	DMSO-d_6	445	3	45
131		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.6(1H,m),4.4(2H,s),3.9(1H,m),3.8-3.7(3H,m),3.1(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m),1.0(1H,m),0.5(2H,m),0.3(2H,m)	DMSO-d_6	429	3	57

Table 19. (continued)

Exemp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
132		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.4(2H,s),3.9(1H,m),3.8(3H,m),3.7(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.9(1H,m),1.3-1.1(4H,m),0.9(6H,d)	DMSO-d_6	431	3	76
133		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.6(2H,s),4.4(2H,s),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.5(1H,s),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	413	3	49
134		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.4(2H,s),4.1(2H,t),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.1(1H,m),2.9-2.7(2H,m),2.8(1H,s),2.5(2H,t),1.3-1.1(4H,m)	DMSO-d_6	427	3	59
135		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.4(2H,s),4.1(2H,t),3.9(1H,m),3.8(1H,m),3.7(1H,m),3.3(2H,s),3.2(3H,s),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	419	1.5	47
136		8.6(1H,s),7.8(1H,d),7.2(1H,d),4.4(2H,s),4.3(2H,t),3.9(1H,m),3.8(3H,m),3.7(1H,m),3.0(1H,m),2.9-2.7(2H,m),1.3-1.1(4H,m)	DMSO-d_6	437	2	53

Table 20. Examples 137 to 146



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
137		8.8(1H,s),7.8(1H,d),4.7(1H,m),4.5(2H,s),4.3(1H,m),4.1(1H,m),3.9(1H,m),3.0(1H,m),2.8-2.7(2H,m),2.65(3H,s),1.3(2H,m),1.0(2H,m),0.9(6H,d)	DMSO-d_6	447	9	57
138		8.8(1H,s),7.8(1H,d),4.8(1H,m),4.7(2H,s),4.3(1H,m),4.2(1H,m),3.9(1H,m),3.0(1H,m),2.9-2.7(2H,m),2.7(3H,s),2.2(2H,m),2.1(2H,m),1.6(1H,m),1.5(1H,m),1.3(2H,m),0.95(2H,m)	DMSO-d_6	459	12	65
139		8.8(1H,s),7.8(1H,d),4.7(1H,m),4.5(2H,s),4.3(1H,m),4.2(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.8(2H,m),2.7(3H,s),1.7(4H,s),1.6(2H,m),1.5(2H,m),1.3(2H,m),0.9(2H,m)	DMSO-d_6	473	12	63
140		8.8(1H,s),7.8(1H,d),4.8(1H,m),4.6(2H,s),4.3(1H,m),4.2(1H,m),4.0(1H,m),3.8-3.6(4H,m),3.1(1H,m),2.9-2.7(2H,m),2.7(3H,s),2.3-1.9(2H,m),1.3(2H,m),0.9(2H,m)	DMSO-d_6	475	12	42

Table 20. (continued)

Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
141		8.8(1H,s),7.8(1H,d),4.6 (2H,s),4.3(1H,m),3.9(1H,m), 3.85(2H,dd),3.1(1H,m),3.0-2.8(2H,m),2.7(3H,s),1.3(2H, m),1.1(1H,m),0.9(2H,m), 0.5(2H,m),0.3(2H,m)	DMSO $-d_6$	459	12	63
142		8.8(1H,s),7.8(1H,d),4.6(2H, s),4.3(1H,m),4.2(1H,m),3.95 (1H,m),3.8(2H,d),3.05(1H, m),2.9-2.7(2H,m),2.7(3H,s), 1.9(1H,m),1.3(2H,m),1.0(2H, m),0.9(6H,d)	DMSO $-d_6$	461	12	68
143		8.8(1H,s),7.8(1H,d),4.62 (2H,s),4.60(2H,s),4.3(1H, m),4.1(1H,m),3.9(1H,m),3.5 (1H,s),3.0(1H,m),2.7(3H,s), 2.9-2.7(2H,m),1.3(2H,m), 1.0(2H,m)	DMSO $-d_6$	443	12	30
144		8.8(1H,s),7.8(1H,d),4.6(2H, s),4.3(1H,m),4.2(1H,m), 4.15(2H,t),3.1(1H,m),2.9-2.7(2H,m),2.8(1H,s),2.7(3H, s),2.5(3H,t),1.3(2H,m), 0.9(2H,m)	DMSO $-d_6$	457	12	52
145		8.8(1H,s),7.8(1H,d),4.6(2H, s),4.3(1H,m),4.15(1H,m),3.9 (1H,m),3.3(2H,s),3.1(3H,s), 2.9(1H,m),2.8-2.6(2H,m), 2.7(3H,s),1.3(2H,m), 0.9(2H,m)	DMSO $-d_6$	449	8	39
146		8.8(1H,s),7.8(1H,d),4.6(2H, s),4.3(2H,t),4.25(1H,m),4.2 (1H,m),3.9(1H,m),3.8(2H,t), 2.9-2.7(2H,m),2.7(3H,s),1.3 (2H,m),1.0(2H,m)	DMSO $-d_6$	467	12	57

Table 21. Examples 147 to 156



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
147		8.4(1H,s),7.7(2H,br),4.5 (1H,m),4.3(2H,s),4.0-3.8 (3H,m),3.2(1H,m),2.8-2.6 (2H,m),1.1(3H,s),0.9 (6H,d)	DMSO -d_6	450	5	73
148		8.3(1H,s),7.3(2H,br),4.8 (1H,m),4.3(2H,s),4.0-3.8 (3H,m),2.8-2.6(2H,m),2.2 (2H,m),2.1(2H,m),1.6(1H,m), 1.5(1H,m),1.1(4H,m)	DMSO -d_6	462	8	64
149		8.4(1H,s),7.4(2H,br),4.7 (1H,m),4.5(2H,s),4.2(1H,m), 3.9(1H,m),3.7(1H,m),3.0(1H, m),2.8-2.6(2H,m),1.7(4H,s), 1.6(2H,m),1.5(2H,m),1.1 (4H,m)	DMSO -d_6	476	8	61
150		8.4(1H,s),7.4(2H,br),4.8 (1H,m),4.6(2H,s),4.2(1H,m), 4.0(1H,m),3.8-3.6(4H,m), 3.0(1H,m),2.8-2.6(2H,m), 2.3-1.9(2H,m),1.2-0.9(4H,m)	DMSO -d_6	478	12	54

Table 21. (continued)

Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
151		8.4(1H,s),7.5(2H,br),4.6 (2H,s),3.9(1H,m),3.8(2H, dd),3.0(1H,m),2.9-2.8(2H, m),1.0(1H,m),0.5(2H,m), 0.3(2H,m)	DMSO -d_6	462	5	82
152		8.4(1H,s),7.5(2H,br),4.5 (2H,s),3.9(1H,m),3.8(2H, dd),3.1(1H,m),2.9-2.7(2H, m),1.9(1H,m),1.2-1.1(4H,m), 0.9(6H,d)	DMSO -d_6	464	6	75
153		8.4(1H,s),7.4(2H,br),4.6 (2H,s),4.59(2H,m),4.2(1H, m),3.9(1H,m),3.7(1H,m),3.5 (1H,s),3.0(1H,m),2.8-2.6 (2H,m),1.1(4H,s)	DMSO -d_6	446	4	50
154		8.4(1H,s),7.5(2H,br),4.4 (2H,s),4.1(1H,m),4.0(2H,t), 3.9(1H,m),3.8(1H,m),3.1(1H, m),2.8-2.7(2H,m),2.8(1H,s), 2.5(2H,t),1.2-0.9(4H,m)	DMSO -d_6	460	5	70
155		8.4(1H,s),7.4(2H,br),4.4 (2H,s),4.3(2H,t),4.1(1H,m), 3.9(1H,m),3.7(2H,t),3.6(1H, m),3.3(2H,s),3.0(3H,s),2.9 (1H,m),2.8-2.6(2H,m), 1.3-0.9(4H,m)	DMSO -d_6	452	3	60
156		8.4(1H,s),7.4(2H,br),4.4 (2H,s),4.3(2H,t),4.0(2H,m), 3.9(1H,m),3.8(2H,t),3.7(1H, m),3.2(1H,m),2.9-2.7(2H,m), 1.1(4H,s)	DMSO -d_6	470	5	72

Table 22. Examples 157 to 166



Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (min)	Yield (%)
157		8.8(1H,s),8.1(1H,d),7.8(1H, m),7.6(1H,dd),7.3(1H,dd), 4.6(1H,m),4.3(2H,s),4.0(1H, m),3.9(1H,m),3.0(1H,m), 2.8-2.6(2H,m),0.9(6H,d)	DMSO -d_6	490	15	64
158		8.8(1H,s),8.1(1H,d),7.8(1H, m),7.6(1H,dd),7.3(1H,dd), 4.7(1H,m),4.4(2H,s),4.0(1H, m),3.9(1H,m),3.0(1H,m),2.8-2.6(2H,m),2.2(2H,m),2.1(2H, m),1.7(1H,m),1.5(1H,m)	DMSO -d_6	502	20	61
159		8.8(1H,s),8.1(1H,d),7.8(1H, m),7.6(1H,dd),7.3(1H,dd), 4.7(1H,m),4.4(2H,s),4.0(1H, m),3.9(1H,m),3.0(1H,m),2.8-2.6(2H,m),2.2(2H,m),2.1(2H, m),1.7(1H,m),1.5(1H,m)	DMSO -d_6	516	35	70
160		8.8(1H,s),8.1(1H,d),7.8(1H, m),7.6(1H,dd),7.3(1H,dd), 4.8(1H,m),4.4(2H,s),4.0(1H, m),3.9(1H,m),3.8-3.6(4H, m),3.0(1H,m),2.9-2.6(2H, m),2.3-1.9(2H,m)	DMSO -d_6	518	35	55

Table 22. (continued)

Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (min)	Yield (%)
161		8.8(1H,s),8.1(1H,d),7.8(1H,dd),7.6(1H,dd),7.3(1H,dd),4.6(2H,s),4.2(1H,m),3.9(1H,m),3.8(2H,dd),3.0(1H,m),2.8-2.6(2H,m),1.1(1H,m),0.5(2H,m),0.3(2H,m)	DMSO-d_6	502	30	65
162		8.8(1H,s),8.1(1H,d),7.8(1H,dd),7.6(1H,dd),7.3(1H,dd),4.6(2H,s),4.0(1H,m),3.9(1H,m),3.8(2H,d),3.0(1H,m),2.8-2.6(2H,m),1.9(1H,m),0.9(6H,d)	DMSO-d_6	504	20	70
163		8.79(1H,s),8.01(1H,d),7.8(1H,m),7.6(1H,dd),7.3(1H,dd),4.73(2H,s),4.61(2H,s),4.21(1H,m),3.75(1H,m),3.50(1H,s),3.36(2H,s),3.08(1H,m),2.90-2.70(2H,m)	DMSO-d_6	436	60	52
164		8.8(1H,s),8.1(1H,d),7.8(1H,m),7.6(1H,dd),7.3(1H,dd),4.6(2H,s),4.1(1H,m),4.0(2H,t),3.9(1H,m),3.0(1H,m),2.8-2.6(2H,m),2.7(1H,s),2.5(2H,t)	DMSO-d_6	500	25	53
165		8.8(1H,s),8.1(1H,d),7.8(1H,m),7.6(1H,dd),7.3(1H,dd),4.6(2H,s),4.1(1H,m),3.9(1H,m),3.3(2H,s),3.1(3H,s),3.0(1H,m),2.8-2.6(2H,m)	DMSO-d_6	492	30	47
166		8.8(1H,s),8.1(1H,d),7.8(1H,m),7.6(1H,dd),7.3(1H,m),4.6(2H,s),4.3(2H,t),4.1(1H,m),3.9(1H,m),3.8(2H,t),3.1(1H,m),2.8-2.6(2H,m)	DMSO-d_6	510	15	51

Table 23. Examples 167 to 176



Exp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
167		8.8(1H,s),7.8(1H,d),4.6(1H,m),4.5(2H,q),4.4(2H,s),4.2(1H,m),3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),1.45(3H,t),0.9(6H,d)	DMSO-d_6	423	4.5	82
168		8.8(1H,s),7.8(1H,d),4.7(1H,m),4.5(2H,q),4.4(2H,s),4.2(1H,m),4.1(1H,m),3.1(1H,m),2.9-2.7(2H,m),2.2(2H,m),2.1(2H,m),1.7(1H,m),1.6(1H,m),1.45(3H,t)	DMSO-d_6	435	5	73
169		8.8(1H,s),7.8(1H,d),4.75(1H,m),4.6(2H,s),4.5(2H,q),4.2(1H,m),3.9(1H,m),3.0-2.7(2H,m),1.8(4H,s),1.65(2H,s),1.5(2H,s),1.4(3H,t)	DMSO-d_6	449	5	77
170		8.7(1H,s),7.8(1H,d),4.8(1H,m),4.55(2H,s),4.5(2H,dd),4.15(1H,m),3.85(1H,m),3.7(2H,m),3.1(1H,m),2.9-2.7(2H,m),2.1-1.9(2H,m),1.5(3H,t)	DMSO-d_6	451	6	71

Table 23. (continued)

Examp. No.	R	^{1}H NMR, δ(ppm)	NMR solv.	FAB, MS (M+1)	Reac. time (hr)	Yield (%)
171		8.8(1H,s),7.8(1H,d),4.6 (2H,s),4.45(2H,m),4.25(1H, m),3.9(2H,dd),3.7(1H,m), 3.1(1H,m),1.45(3H,t),0.5 (2H,m),0.25(2H,m)	DMSO $-d_6$	435	5	84
172		8.8(1H,s),7.8(1H,d),4.6(2H, s),4.5(2H,q),4.2(1H,m),3.9 (1H,m),3.85(2H,dd),3.1(1H, m),2.9-2.7(2H,m),1.9(1H,m), 0.9(6H,d)	DMSO $-d_6$	437	4	70
173		8.8(1H,s),7.8(1H,d),4.62 (2H,s),4.5(2H,q),4.4(2H,s), 4.2(1H,m),3.9(1H,m),3.5(1H, s),3.1(1H,m),2.9-2.7(2H,m), 1.45(3H,t)	DMSO $-d_6$	419	3	50
174		8.8(1H,s),7.8(1H,d),4.5(2H, dd),4.2(1H,m),4.15(2H,t), 3.9(1H,m),3.1(1H,m),2.9-2.7(2H,m),2.8(1H,s),2.5(2H, t),1.5(3H,t)	DMSO $-d_6$	433	4.5	72
175		8.8(1H,s),7.8(1H,d),4.6(2H, s),4.5(2H,dd),4.15(1H,m), 3.9(1H,m),3.3(2H,s),3.1(3H, s),2.9(1H,m),2.8(1H,m),2.6 (1H,m),1.5(3H,t)	DMSO $-d_6$	425	2	39
176		8.8(1H,s),7.8(1H,d),4.6(2H, s),4.5(2H,dd),4.3(2H,t),4.2 (1H,m),3.9(1H,m),3.8(2H,t), 2.9-2.7(2H,m),1.5(3H,t)	DMSO -d6	443	2	57

Example 177

Synthesis of 7-(4-amino-3-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid



2.33g (10 mmole) of 1-cyclopropyl-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and 4.27g (11.5 mmole) of 4-aminomethyl-pyrrolidin-3-one O-methyloxime ditrifluoroacetate were added to 23ml of dry acetonitrile. Then, 4.6g (30 mmole) of 1,8-diazabicyclo[5.4.0]undec-7-ene was added thereto and the mixture was refluxed for 1.5 hours under heating and then cooled down to room temperature. 15ml of distilled water was added to the reaction solution. The precipitated solid product was separated and dried to obtain 2.24g (Yield: 55%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.6(1H, s), 7.75(1H, d), 4.35(2H, s), 4.1-3.9(2H, m), 3.8(3H, s), 3.7(1H, m), 3.35(1H, m), 2.9-2.6(2H, m), 1.25 (2H, d), 0.95(2H, s)

FAB MS (POS) : [M+H] = 407

Example 178

Synthesis of 7-(4-aminomethyl-3-methoxyiminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic aicd



141mg (0.5 mmole) of 1-cyclopropyl-8-chloro-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and 205mg (0.55 mmole) of 4-aminomethylpyrrolidin-3-one O-methyloxime ditrifluoroacetate were reacted for one hour according to the same manner as Example 177. Then, the reaction solution was concentrated and the residue was purified with preparative HPLC to obtain 80mg (Yield: 42%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.7(1H, s), 7.85(1H, d), 4.4(1H, m), 3.75(3H, s), 3.7(3H, m), 3.4(2H, m), 3.0-2.7(2H, m), 1.25(2H, d), 1.0(2H, s)

FAB MS(POS) : [M+H] = 423

Example 179

Synthesis of 7-(4-aminomethyl-3-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid



132mg (0.5 mmole) of 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and 205mg (0.55 mmole) of 4-aminomethylpyrrolidin-3-one O-methyloxime ditrifluoroacetate were reacted for 3 hours according to the same manner as Example 177. Then, the reaction solution was concentrated and the residue was purified with preparative HPLC to obtain 73mg (Yield: 37%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.6(1H, s), 7.85(1H, d), 7.2(1H, d), 4.4(2H, d), 3.9(1H, m), 3.85(3H, s), 3.8-3.65(2H, m), 3.0(1H, m), 2.9-2.7(2H, m), 1.3(2H, m), 1.1(2H, m)

FAB MS(POS) : [M+H] = 389

Example 180

Synthesis of 7-(4-aminomethyl-3-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid



141mg (0.5 mmole) of 1-cyclopropyl-7-chloro-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid and 205mg (0.5 mmole) of 4-aminomethylpyrrolidin-3-one O-methyloxime ditrifluor-

oacetate were reacted for 0.5 hour according to the same manner as Example 177 to obtain 167mg (Yield: 85%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.6(1H, s), 8.05(1H, d), 4.55(2H, s), 4.3(1H, m), 3.85(3H, s, 1H, m), 3.7 (1H, m), 3.1-3.0(2H, m), 1.2-1.0(4H, m)

FAB MS(POS) : [M+H] = 390

Example 181

Synthesis of 7-(4-aminomethyl-3-methoxyiminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid



177mg (0.5 mmole) of 1-(2,4-difluorophenyl)-7-chloro-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid and 205mg (0.55 mmole) of 4-aminomethylpyrrolidin-3-one O-methyloxime ditrifluoroacetate were reacted for 0.5 hour according to the same manner as Example 177 to obtain 59mg (Yield: 25%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.85(1H, s), 8.05(1H, d), 7.75(1H,

dd), 7.6(1H, dd), 7.35(1H, dd), 4.3(2H, m), 3.8(3H, s, 1H, m), 3.6(1H, m), 3.0 (1H, m), 2.7(2H, m)

FAB MS(POS) : [M+H] = 462

Example 182

Synthesis of 1-cyclopropyl-5-amino-6,8-difluoro-7-(4-aminomethyl-3-methyloximinopyrrolidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid



143mg (0.5 mmole) of 1-cyclopropyl-5-amino-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and 205mg (0.55 mmole) of 4-aminomethylpyrrolidin-3-one O-methyloxime ditrifluoroacetate were refluxed for 4 hours under heating according to the same manner as Example 177. Then, the reaction solution was concentrated and the residue was purified with preparative HPLC to obtain 84mg (Yield: 40%) of the title compound.

^{1}H NMR (DMSO-d_6, ppm) : δ 8.49(1H, s), 7.28(2H, bs), 4.3(2H, s), 3.9(2H, m), 3.8(3H, s), 3.7(1H, m), 2.6-2.8(3H, m), 1.05(4H, m)

FAB MS(POS) : $[M+H]^+$ = 422

Examples 183 to 202

The compounds prepared in Preparations 40 and 55 to 57 were treated according to the same procedure as Example 177 to 182 to prepare the respective compounds 183 to 202 of which NMR and MS data are listed in the following Table 24.

Table 24. Examples 183 to 202



Ex. No.	Q	R_1	R_2	^1H NMR(DMSO-d_6) δ(ppm)	FAB MS (POS) [M-H]	Reac. Time (hr)	Yield (%)
183	CF		H	8.8(1H,s),7.9(1H,d),4.35(1H,m),3.8(2H,m),3.7(2H,m),3.4(1H,m),3.0(2H,m),1.2-1.0(4H,m)	393	2.5	41
184	CF		Et	8.8(1H,s),7.9(1H,d),4.4(1H,m),4.2(2H,q),4.1-3.9(2H,m),3.4(2H,m),2.8(2H,m),1.4(3H,t),1.25-1.0(4H,m)	421	2	38
185	CF		Ph	8.8(1H,s),7.9(1H,d),7.3-7.1(5H,m),4.3(1H,m),3.9-3.7(3H,m),3.4(2H,m),2.8(2H,m),1.2(2H,d),1.05(2H,s)	469	4	29
186	CF		tBu	8.8(1H,s),7.9(1H,d),4.35(1H,d),4.1-3.9(3H,m),3.4(2H,m),2.9-2.7(2H,m),1.35(9H,s),1.2-0.95(4H,m)	449	2	35
187	CCl		H	8.9(1H,s),7.9(1H,d),4.4(1H,m),3.8(2H,m),3.7(2H,m),3.4(1H,m),2.9(2H,m),1.25(2H,m),1.1(2H,s)	409	1.5	39
188	CCl		Et	8.9(1H,s),7.9(1H,d),4.35(1H,m),4.2(2H,q),3.95-3.75(3H,m),3.7(2H,m),3.4(2H,m),2.85-2.7(2H,m),1.4(3H,t),1.3-1.15(4H,m)	437	1.5	37

Table 24. (continued)

Ex. No.	Q	R_1	R_2	^1H NMR(DMSO-d_6) δ(ppm)	FAB MS (POS) [M+H]	Reac. Time (hr)	Yield (%)
189	CCl		Ph	8.9(1H,s),7.9(1H,d),7.3-7.1 (5H,m),4.35(1H,m),4.1-3.9 (3H,m),3.65(2H,m),3.35(2H, m),2.8-2.7(2H,m),1.15(2H,d), 0.95(2H,s)	485	4.5	25
190	CCl		tBu	8.9(1H,s),7.85(1H,d),4.3(1H, m),3.95-3.8(3H,m),3.7(2H,m), 3.4(2H,m),2.8(2H,m),1.3(9H, s),1.2-1.0(4H,m)	465	3	51
191	CH		H	8.6(1H,s),7.85(1H,d),7.2(1H, d),4.4(1H,m),3.9(2H,m),3.8-3.65(3H,m),2.9-2.7(2H,m),1.3 (2H,d),1.1(2H,s)	375	2.2	42
192	CH		Et	8.6(1H,s),7.8(1H,d),7.2(1H, d),4.4(1H,m),4.25(2H,q),3.9-3.7(3H,m),3.5(2H,m),2.9-2.7 (2H,m),1.3(3H,t),1.25-0.95 (4H,m)	403	1.5	40
193	CH		Ph	8.6(1H,s),7.8(1H,d),7.5-7.2 (5H,m,1H,d),4.35(1H,m),4.0-3.8(3H,m),3.5(2H,m),2.85-2.7 (2H,m),1.3(2H,d),1.15(2H,s)	451	4.5	31
194	CH		tBu	8.6(1H,s),7.75(1H,d),7.2(1H, d),4.35(1H,m),4.0-3.8(3H,m), 3.5(2H,m),2.9-2.7(2H,m),1.4 (9H,s),1.2-1.05(4H,m)	431	3	43
195	N		H	8.6(1H,s),8.1(1H,d),4.5(2H, s),4.3(1H,m),3.8(1H,m),3.65 (1H,m),3.35(1H,m),3.0-2.9 (2H,m),1.2-1.0(4H,m)	376	1	61
196	N		Et	8.6(1H,s),8.05(1H,d),4.55 (2H,s),4.3(1H,m),4.25(2H, q),3.8(1H,m),3.7(1H,m),3.4 (1H,m),3.0-2.85(2H,m),1.35 (3H,t),1.2-0.95(4H,m)	404	1	57

Table 24. (continued)

Ex. No.	Q	R_1	R_2	^1H NMR(DMSO-d_6) δ(ppm)	FAB MS (POS) [M+H]	Reac. Time (hr)	Yield (%)
197	N		Ph	8.6(1H,s),8.1(1H,d),7.7-7.3 (5H,m),4.6(2H,s),4.35(1H,m), 3.9(1H,m),3.75(1H,m),3.4(1H, m),3.05-2.8(3H,m),1.25(2H, d),1.05(2H,s)	452	1	40
198	N		tBu	8.6(1H,s),8.05(1H,d),4.55 (2H,s),4.35(1H,m),3.95(1H, m),3.7(1H,m),3.35(1H,m),3.0-2.85(2H,m),1.35(9H,s),1.15 (2H,d),1.0(2H,s)	432	1.5	54
199	N		H	8.85(1H,s),8.1(1H,d),7.75 (1H,m),7.6(1H,dd),7.35(1H, dd),4.3(1H,m),3.8(3H,m),3.6 (1H,m),3.0(1H,m),2.7(2H,m)	448	1	33
200	N		Et	8.85(1H,s),8.05(1H,d),7.75 (1H,m),7.6(1H,dd),7.35(1H, dd),4.3(1H,m),4.25(2H,q), 3.75(3H,m),3.6(2H,m),2.95 (2H,m),2.7-2.6(2H,m),1.4 (3H,t)	476	1	37
201	N		Ph	8.85(1H,s),8.1(1H,d),7.75 (1H,m),7.6(1H,dd),7.55-7.35 (5H,m,1H,dd),4.35(1H,m),3.75 (3H,m),3.65(2H,m),3.0(2H,m), 2.85(2H,m)	524	1.5	29
202	N		tBu	8.85(1H,s),8.05(1H,d),7.75 (1H,m),7.55(1H,dd),7.3(1H, dd),4.3(1H,m),3.8(3H,m),3.55 (2H,m),2.9(2H,m),2.7-2.65 (2H,m),1.3(9H,s)	504	0.5	41

Example 203: Separation of *E*, *Z* isomer of the compound prepared in Example 180



Z-isomer (anti)



E-isomer (syn)

3.9g (10mmol) of the 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid prepared in Example 180 was completely dissolved in 100ml of a solvent mixture of dichloromethane and methanol (9/1, v/v) under reflux. 1.0g (10.5 mmol) of methanesulfonic acid was added thereto in one portion while stirring. The resulting solution was heated overnight. After the heated solution was cooled to -10°C, it was filtered. The filtrate was twice washed with 10ml of methanol, then washed with 20ml of diethylether, and finally dried under nitrogen flow to obtain 3.6g (Yield 75%) of a beige cake containing oxime *Z/E* mixture (80:20 on HPLC).

E-isomer : t_R = 6.64min

Z-isomer : t_R = 8.37min

250mg of the powder thus obtained was dissolved in 3ml of water and the resulting solution was separated on Preparative HPLC. The desired fraction was collected and readily adjusted to

about pH 6.5 by adding 1N NaOH. After the acetonitrile was evaporated, the resulting suspension was filtered and washed with water (2ml x 3). The wet cake thus obtained was extracted with chloroform (20ml x 2). The remaining solvent was evaporated and the residue was dried in vacuo to obtain 30mg of white solid. The *E*- and *Z*-isomers were collected using the same procedure.

E-isomer

^{1}H NMR($CDCl_3$, δ, ppm) : 8.69(1H,s), 8.05(1H,d,J=12.5Hz), 4.60(2H,dd,J=19Hz), 4.12(2H,dd,J=8Hz), 4.00(3H,s), 3.71(1H,m), 3.55(1H,m), 3.10(2H,d), 1.36(2H,m), 1.14(2H,m)

Z-isomer($CDCl_3$, δ, ppm) : 8.70(1H,s), 8.05(1H,d), 4.61(2H,s), 4.28(1H,dd), 3.99(3H,s), 3.90(1H,m), 3.69(1H,m), 3.10(1H,m), 3.00(2H,d), 1.30(2H,,), 10.5(2H,m)

Example 204: Synthesis of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate

3.89g (10mmol) of 7-(4-aminomethyl-3-methyloxyminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid prepared as in Example 180 was suspended in 110ml of a solvent mixture of dichloromethane and ethanol (8/2, v/v). 0.94g (9.8mmol) of methanesulfonic acid was added dropwise thereto and the resulting solution was thoroughly stirred for 1 hour at 0°C. The solid thus produced was filtered, washed with ethanol, and then dried to obtain 4.55g of the title compound.

m.p. : 195°C (dec.)

^{1}H NMR(DMSO-d_6) δ (ppm) : 8.57(1H,s), 8.02(1H,d)

Example 205: Synthesis of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate·3 hydrate

A sonicator filled with water was adjusted to 40°C and was sealed with a lid. Then, a nitrogen introducing tube and a nitrogen excreting tube were connected to the vessel. When the pressure of the dried nitrogen introduced through the nitrogen introducing tube was adjusted to 20psi, the relative humidity of the humidified nitrogen excreted through the excreting tube was more than 93%. 1g of the anhydride having moisture content of about 2.5% prepared in Example 204 was introduced into a fritted filter and the humidified nitrogen prepared according to the above mentioned process was passed through. Samples were taken after 0, 5, 10, 20, 30, and 60 minutes, respectively, and the moisture content with the lapse of time was measured. From the results shown in Figure 8, it can be seen that moisture content of about 10% is constantly maintained when the humidifying procedure is carried out over 30 minutes. The X-ray diffraction pattern of the humidified sample was identical to that the 3 hydrate obtained after recrystallization.

Example 206: Synthesis of 7-(4-aminomethyl-3-methyloxyiminopyr-

rolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate·1.5 hydrate

The title compound can be prepared by two different processes.

In the first process, 1.0g of the anhydride prepared in Example 204 was dissolved in 17ml of a mixture of water and acetone (10/7, v/v). The solvent was slowly evaporated in darkness leaving 0.8g of the title compound as a solid.

In the second process, 5.0g of the anhydride prepared in Example 204 was added to 10ml of water and the mixture was heated to about 45°C in order to dissolve the anhydride. After 20ml of ethanol was added thereto, the resulting solution was stirred and then allowed to stand to form a solid. The solid thus produced was filtered and dried under nitrogen flow to obtain 2.6g of the title compound.

Biological Example 1

In vitro antibacterial activity test

The antibacterial activity of the compounds according to the present invention was determined by measuring their minimum inhibitory concentrations (MIC, μg/ml) against standard strains, clinically isolated strains and strains resistant to some antibacterial agents. In this test, the known antibacterial compounds, ofloxacin and ciprofloxacin, were used as the comparative agents. The minimum inhibitory concentration could be determined

by diluting the test compounds according to a two-times dilution method, dispersing the diluted test compounds in Mueller-Hinton agar medium and then inoculating 5μl of the standard strain having 10^7 CFU per ml to the medium, which is then incubated for 18 hours at 37°C. The measured results are described in the following Table 25.

Table 25. Minimum Inhibitory Concentration of the test compounds (μg/ml)

Test Strains \ Examples	1	12	34	56	89
Staphylococcus aureus 6538p	≤0.008	≤0.008	≤0.008	≤0.008	≤0.008
Staphylococcus aureus giorgio	≤0.008	≤0.008	≤0.008	≤0.008	≤0.008
Staphylococcus aureus 77	≤0.008	≤0.008	≤0.008	≤0.008	≤0.008
Staphylococcus aureus 241	2	1	4	2	1
Staphylococcus epidermidis 887E	≤0.008	≤0.008	≤0.008	≤0.008	≤0.008
Staphylococcus epidermidis 178	2	0.5	2	2	0.5
Streptococcus faecalis 29212	0.031	0.031	0.13	0.016	0.063
Bacillus subtilis 6633	≤0.008	≤0.008	≤0.008	≤0.008	≤0.008
Micrococcus luteus 9341	0.063	0.13	0.13	0.063	0.25
Escherichia coli 10536	≤0.008	≤0.008	0.016	≤0.008	0.016
Escherichia coli 3190Y	≤0.008	0.016	≤0.008	≤0.008	0.016
Escherichia coli 851E	0.016	0.063	0.13	≤0.008	0.063
Escherichia coli TEM3 3455E	0.25	0.5	1	0.5	0.25
Escherichia coli TEM5 3739E	0.063	0.25	0.5	0.25	0.13
Escherichia coli TEM9 2639E	0.063	0.25	0.13	0.063	0.063
Pseudomonas aeruginosa 1912E	1	2	0.5	2	2
Pseudomonas aeruginosa 10145	2	0.5	2	2	2
Acinetobacter calcoaceticus 15473	≤0.008	0.016	0.031	≤0.008	0.031
Citrobacter diversus 2046E	0.063	0.13	0.25	0.016	0.13
Enterobacter cloacae 1194E	0.031	0.13	0.25	0.031	0.13
Enterobacter cloacae P99	≤0.008	0.063	0.063	≤0.008	0.016
Klebsiella aerogenes 1976E	0.25	1	0.5	0.5	0.5
Klebsiella aerogenes 1082E	0.063	0.13	0.031	0.016	0.25
Salmonella typimurium 14028	0.13	0.25	0.063	0.031	0.13

Table 25. (continued)

Test Strains \ Examples	97	102	103	104	177
Staphylococcus aureus 6538p	≤0.008	0.016	≤0.008	≤0.008	≤0.008
Staphylococcus aureus giorgio	≤0.008	≤0.008	≤0.008	≤0.008	≤0.008
Staphylococcus aureus 77	0.016	0.016	≤0.008	≤0.008	0.016
Staphylococcus aureus 241	2	4	4	8	0.5
Staphylococcus epidermidis 887E	≤0.008	≤0.008	≤0.008	0.016	≤0.008
Staphylococcus epidermidis 178	1	1	4	4	1
Streptococcus faecalis 29212	0.063	0.063	0.031	0.031	0.031
Bacillus subtilis 6633	≤0.008	≤0.008	≤0.008	≤0.008	≤0.008
Micrococcus luteus 9341	0.063	0.063	0.13	0.13	0.063
Escherichia coli 10536	≤0.008	≤0.008	≤0.008	≤0.008	≤0.008
Escherichia coli 3190Y	≤0.008	≤0.008	≤0.008	≤0.008	≤0.008
Escherichia coli 851E	0.031	0.063	≤0.008	≤0.008	0.031
Escherichia coli TEM3 3455E	0.13	0.5	0.13	0.25	0.25
Escherichia coli TEM5 3739E	0.063	0.25	0.063	0.13	0.13
Escherichia coli TEM9 2639E	0.031	0.063	0.031	0.031	0.063
Pseudomonas aeruginosa 19129	1	2	0.5	1	0.5
Pseudomonas aeruginosa 10145	1	2	0.5	1	0.5
Acinetobacter calcoaceticus 15473	0.016	0.063	0.031	≤0.008	0.13
Citrobacter diversus 2046E	0.063	0.13	0.13	≤0.008	0.031
Enterobacter cloacae 1194E	0.063	0.25	0.016	≤0.008	0.063
Enterobacter cloacae P99	≤0.008	0.031	≤0.008	0.016	0.016
Klebsiella aerogenes 1976E	0.25	0.5	0.063	0.13	0.13
Klebsiella aerogenes 1082E	0.13	0.25	0.031	0.031	0.063
Salmonella typimurium 14028	0.13	0.25	0.031	0.031	0.063

Table 25. (continued)

Test Strains \ Examples	178	179	180	OFLX	CFLX
Staphylococcus aureus 6538p	0.031	≤0.008	≤0.008	0.25	0.13
Staphylococcus aureus giorgio	0.016	0.016	≤0.008	0.25	0.25
Staphylococcus aureus 77	0.031	0.031	≤0.008	0.25	0.25
Staphylococcus aureus 241	1	2	2	64	64
Staphylococcus epidermidis 887E	0.031	0.016	≤0.008	0.25	0.13
Staphylococcus epidermidis 178	1	2	2	32	128
Streptococcus faecalis 29212	0.063	0.031	0.063	2	0.5
Bacillus subtilis 6633	0.016	≤0.008	≤0.008	0.063	0.031
Micrococcus luteus 9341	0.25	0.13	0.13	2	2
Escherichia coli 10536	0.031	≤0.008	≤0.008	0.031	≤0.008
Escherichia coli 3190Y	0.016	≤0.008	≤0.008	0.016	≤0.008
Escherichia coli 851E	0.063	≤0.008	≤0.008	0.063	0.016
Escherichia coli TEM3 3455E	1	0.13	0.25	0.5	0.25
Escherichia coli TEM5 3739E	0.5	0.063	0.13	0.5	0.13
Escherichia coli TEM9 2639E	0.25	0.031	0.031	0.063	0.031
Pseudomonas aeruginosa 1912E	0.5	0.25	0.25	0.5	0.31
Pseudomonas aeruginosa 10145	1	0.25	0.25	2	0.25
Acinetobacter calcoaceticus 15473	0.13	0.016	0.063	0.25	0.25
Citrobacter diversus 2046E	0.13	0.031	0.016	0.063	0.016
Enterobacter cloacae 1194E	0.13	0.031	0.031	0.063	0.031
Enterobacter cloacae P99	0.063	0.008	≤0.008	≤0.008	≤0.008
Klebsiella aerogenes 1976E	0.5	0.13	0.13	0.25	0.13
Klebsiella aerogenes 1082E	0.25	0.031	0.016	0.063	≤0.008
Salmonella typimurium 14028	0.063	0.063	0.031	0.13	0.031

Note) OFLX = Ofloxacin
CFLX = Ciprofloxacin

Biological Example 2

Pharmacokinetic test

The pharmacokinteic property parameters of the compounds of the present invention were determined using SD rats (male) weighing about 230±10g. Specifically, the test compounds of the present invention were administered in an amount of 20mg/kg of body weight to test rats via femoral veins. Then, bloods were collected at certain intervals after administration of the test compounds from femoral veins and analyzed by means of Agar Well Method to measure the blood concentration of the test compounds from which pharmacokinetic parameters, half life ($T_{1/2}$) and AUC (area under the curve) were calculated. The obtained results are described in the following Table 26.

Table 26. Pharmacokinetic parameters

	Route	$T_{1/2}$ (hr)	C_{max} (μg/ml)	T_{max} (hr)	F (%)
CFLX	IV	1.76±0.035			71
	PO	1.7 ±0.108	1.34±0.368	1.13±0.605	
EX.89	IV	2.29±1.13			>100
	PO	6.69±2.78	4.89±2.23	2.18±0.77	
EX.177	IV	1.92±0.38			47.23
	PO	3.93±1.31	0.37±0.11	0.51±0.33	

Note: CFLX = Ciprofloxacin
IV = Intravenous
PO = Per oral
$T_{1/2}$ = Biological half life

C_{max} = Maximum blood concentration
T_{max} = Time showing maximum blood concnetration after administration of the test compound
F = Bioavailability

Biological Exarple 3

Acute oral toxicity test

To determine the acute oral toxicity of the compounds prepared in Examples 1 and 34, the test solution containing the compounds in various concentrations were orally administered to ICR male mouse in an amount of 10ml per kg of body weight. For 7 days after administration, the lethality and the conditions of test mouse were observed, from which LD_{50} value (mg/kg) was calculated. The obtained results are described in the following Table 27.

Table 27. Toxicity

Test Compound (Example No.)	LD_{50} value (mg/kg)
1	> 3,000
34	> 3,000

Test Example 1: Moisture adsorption test of the anhydride prepared in Example 204

Under various relative humidities at 25°C, the moisture adsorption velocity and the equilibrium moisture content of the

anhydride prepared in Example 203 were determined by means of an automatic moisture adsorption analyzer (MB 300 G Gravimetric Sorption Analyzer). This instrument produces a specific relative humidity at a specific temperature and continuously records the weight change of a sample due to adsorption or desorption of moisture as measured by a micro balance inside the instrument. 16mg of the anhydride sample was loaded on the micro balance and the moisture contained in the sample was removed under a dry nitrogen stream at 50°C. A weight change of less than 5μg per 5 minutes was the criterion for complete dryness. Thereafter, the inner temperature was adjusted to 25°C, and the sample was tested varying the relative humidity from 0 to 95% at 5% intervals. The sample was considered to have reached equilibrium at each relative humidity tested when the weight change was less than 5μg per 5 minutes. Figure 1 shows the moisture adsorption velocity, that is, the time required for the sample to reach equilibrium at each relative humidity from 0 to 95% at 5% intervals. Initial moisture adsorption proceeded very speedily at each relative humidity tested. In most cases, the equilibrium was reached within 2 hours. Figure 2 shows the weight increment(%) at each relative humidity, that is, the equilibrium moisture content. It is clear from figure 2 that the equilibrium moisture content is dependent upon the relative humidity.

Test Example 2 : Thermal analysis of the anhydride prepared in Example 204 and 3 hydrate prepared in Example 205

For the Differential Scanning Calorimetry, METTLER TOLEDO DSC821e and METTLER TOLEDO STARe System were used. 3.7mg of sample was weighed into the aluminum pan, which was then press sealed with an almunum lid. After three tiny needle holes were made on the lid, the sample was tested by heating from normal temperature to 250°C at a rate of 10°C/min. As can be seen from Figure 9, the endothermic peak due to the vaporization of the water molecules contained in the 3 hydrate begins at around 50°C and the exothermic peak due to the thermal decomposition was observed at around 180 to 220°C. In contrast, the anhydride showed only an exothermic peak due to thermal decomposition at around 185 to 220°C without any endothermic peak.

In the thermogravimetric analysis, SEIKO TG/DTA220 was used. 3.8mg of the sample was weighed into an aluminum pan and was heated from normal temperature to 250°C at a rate of 10°C/min according to the temperature raising program. As can be seen from Figure 10, weight decrement was observed at the temperature range of endothermic peak, the extent of which corresponds to the moisture content determined by Karl-Fisher method (Mettler Toledo DL37KF Coulometer).

Test Example 3: Equilibrium moisture content determination of hydrates

Six saturated aqueous salt solutions were introduced into each desiccator to control the inner relative humidity to a specific value as represented in the following Table 28. Then,

equilibrium moisture contents of 3 hydrate and 1.5 hydrate prepared in Examples 205 and 206, respectively, were determined at several relative humidities.

Table 28. Saturated salt solutions inside the desiccator

Salt Solution	Relative Humidity(%) at 25°C
Potassium Acetate	23
Magnesium Chloride	33
Potassium Carbonate	43
Magnesium Nitrate	52
Sodium Nitrite	64
Sodium Chloride	75

Specifically, 100mg of the sample was spread on a pre-weighed Petri dish and the total weight was accurately measured, then three of the sample were placed in each desiccator of Table 28. The desiccators were allowed to stand at normal temperature for 7 days and then the sample was taken to be weighed. After 13 days had passed, one of the three samples inside each desiccator was taken and the moisture content of each was measured by the thermogravimetric analysis described in Test Example 2. Equilibrium moisture content at each relative humidity is represented in Figure 3 (3 hydrate) and Figure 4 (1.5 hydrate). Figure 3 shows that moisture content of the 3 hydrate is maintained around 10% for the whole relative humidity range tested; Figure 4 shows that the moisture content of the 1.5 hydrate is maintained around 5% at the relative humidity of 23 to 64%. Both hydrates are stable

since they keep a constant equilibrium moisture content regardless of the relative humidity change.

Test Example 4 : X-ray diffraction analysis

After 50mg of the anhydride in Example 204, the 3 hydrate in Example 205, and the 1.5 hydrate in Example 206 were each thinly spread on the sample holder, X-ray diffraction analyses (35kV x 20mA Rigaku Gergeflex D/max-IIIC) were performed under the conditions listed below.

-scan speed (2θ) 5°/min
-sampling time : 0.03 sec
-scan mode : continuous
-2θ/θ reflection
-Cu-target (Ni filter)

Results of X-ray diffraction analyses on the anhydride, the 3 hydrate, and the 1.5 hydrate were as depicted in Figure 5, 6, and 7, respectively. From these spectra it can be verified that their crystal forms differ from each other.

Test Example 5 : Chemical stability under heating

The chemical stability of both the 3 hydrate prepared in Example 205 and the 1.5 hydrate prepared in Example 206 were compared with the chemical stability of the anhydride prepared in Example 204 as follows in order to determine the effect on chemical stability of the extent of hydration.

The anhydride and each of the hydrates was introduced into a glass vial and maintained at 70°C. Then, the extent of decomposition with elapsed time was analyzed by liquid chromatography and the results thus obtained are described in teh following Table 29.

Table 29. Thermal stability with elapsed time (at 70°C)

(Unit: %)

Time(week) / Sample	Initial	1	2	3	4
Anhydrate	99	-	97	-	95
3 hydrate	97	-	-	-	94
1.5 hydrate	100	97.25	95.80	97.16	96.17

As can be from Table 29, the 3 hydrate and the 1.5 hydrate both showed the same degree of thermal stability as the anhydride.

Test Example 6: Water solubility of the compound prepared in Example 204

Water solubilities of various salts of the compound, including that of the methanesulfonate prepared in Example 204, were measured. The measurement results are listed in the following Table 30.

Talbe 30. Water Solubility

Sample	Phosphate buffered solution (pH7)	Phosphate buffered solution (pH2)
Free form	0.007	14.6
Tartarate	6.7	15.4
Sulfurate	11.4	8.9
p-Toluenesulfonate	7.5	6.8
Methanesulfonate	>30	>20

As can be seen from the above results, the methanesulfonate shows a water solubility superior to that of the tartarate, the sulfurate, and the p-toluenesulfonate as well as the free form. Therefore, it is identified that the methanesulfonate has a desirable solubility as well as an excellent antibacterial activity.

Biological Example 4: In vitro antibacterial activity test

In orer to determine the antibacterial activitiers of the E- and Z-isomer of the compound 180 which were separated in Example 203, and of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate prepared in Example 204, in vitro antibacterial activities of them were measured using agar medium dilution method. The results were as described in the following Tables 31 and 32. In Table 32, the minimum inhibitory concentration (MIC, μg/ml) was simply calculated in the ratio of weight without considering the molecular weight, and ciprofloxacin was

chosen as the control. From the results, it is identified that the Z-isomer has a superior antibacterial activity to the E-isomer and that the methanesulfonate as well as the free form has an excellent antibacterial activity.

Table 31. In vitro Antibacterial activity (Minimum Inhibitory Concentration : MIC, μg/ml)

Test Strains	*E*-isomer	*Z*-isomer	Ciprofloxacin
Staphylococcus aureus 6538p	0.063	≤0.008	0.13
Staphylococcus aureus giorgio	0.063	≤0.008	0 13
Staphylococcus aureus 77	0.063	0.031	0.25
Staphylococcus aureus 241	16	4	64
Staphylococcus epidermidis 887E	0.031	≤0.008	0.063
Staphylococcus epidermidis 178	32	4	128
Streptococcus faecalis 29212	0.25	0.063	1
Bacillus subtilis 6633	0.031	≤0.008	0.031
Micrococcus luteus 9341	0.5	0.13	2
Escherichia coli 10536	0.031	≤0.008	0.016
Escherichia coli 3190Y	0.016	≤0.008	≤0.008
Escherichia coli 851E	0.063	0.016	≤0.008
Escherichia coli TEM3 3455E	0.5	0.13	0.25
Escherichia coli TEM5 3739E	0.5	0.13	0.13
Escherichia coli TEM9 2639E	0.13	0.031	0.016
Pseudomonas aeruginosa 1912E	1	0.5	0.25
Pseudomonas aeruginosa 10145	2	0.5	0.25
Pseudomonas aeruginosa 6065Y	32	8	4
Acinetobacter calcoaceticus 15473	0.25	0.063	0.25
Citrobacter diversus 2046E	0.13	0.031	0.031
Enterobacter cloacae 1194E	0.13	0.031	0.016
Enterobacter cloacae P99	0.031	≤0.008	≤0.008
Klebsiella aerogenes 1976E	0.25	0.063	0.13
Klebsiella aerogenes 1082E	0.13	0.031	0.016
Proteus vulgaris 6059	1	0.25	0.031
Seratia marsecence 1826E	0.5	0.25	0.063
Salmonella thypimurium 14028	0.13	0.031	0.031

Table 32. In vitro Antibacterial activity (Minimum Inhibitory Concentration: MIC, μg/ml)

Test Strains	Methanesulfonic acid salt	Ciprofloxacin
Staphylococcus aureus 6538p	0.016	0.13
Staphylococcus aureus giorgio	0.016	0.13
Staphylococcus aureus 77	0.031	0.25
Staphylococcus aureus 241	4	128
Staphylococcus epidermidis 887E	0.016	0.013
Staphylococcus epidermidis 178	4	128
Streptococcus faecalis 29212	0.13	0.5
Bacillus subtilis 6633	0.016	0.031
Micrococcus luteus 9341	0.13	2
Escherichia coli 10536	0.008	<0.008
Escherichia coli 3190Y	0.008	<0.008
Escherichia coli 851E	0.016	<0.008
Escherichia coli TEM3 3455E	0.25	0.5
Escherichia coli TEM5 3739E	0.13	0.13
Escherichia coli TEM9 2639E	0.031	0.016
Pseudomonas aeruginosa 1912E	0.25	0.13
Pseudomonas aeruginosa 10145	0.5	0.5
Acinetobacter calcoaceticus 15473	0.031	0.25
Citrobacter diversus 2046E	0.031	0.016
Enterobacter cloacae 1194E	0.031	0.016
Enterobacter cloacae P99	0.016	<0.008
Klebsiella aerogenes 1976E	0.13	0.13
Klebsiella aerogenes 1082E	0.031	0.016
Proteus vulgaris 6059	0.25	0.031
Seratia marsecence 1826E	0.13	0.063
Salmonella thypimurium 14028	0.031	0.031

Although this invention has been described in its preferred form with a certain degree of particularity, it is appreciated by those skilled in the art that the present disclosure of the preferred form has been made only by way of example and that numerous changes in the details of the construction, combination and arrangement of parts may be resorted to without departing from the spirit and scope of the invention.

WHAT IS CLAIMED IS :

1. 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid represent by the following formula :



or its isomer.

2. The compound according to claim 1 in the from of Z isomer.

3. 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate or its hydrate represented by the following formula (H) :



$\cdot CH_3SO_3H \cdot nH_2O$ (H)

or its isomer, in which n denotes 0, 1, 1.5, 2, 2.5, 3, 3.5 or 4.

4. The hydrate according to claim 3, wherein n is 3.

5. The hydrate according to claim 3, wherein its moisture content is 9 to 11% by weight.

6. The hydrate according to claim 3, wherein n is 1.5.

7. The hydrate according to claim 3, wherein its moisture content is 4 to 6% by weight.

8. A process for preparing 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid represented by the following formula:



or its isomer, methanesulfonate and hydrate of the methanesulfonate, which comprises reacting a quinolone derivative represented by the following formula,



in which X represents a halogen, with a pyrrolidine oxime derivative represented by the following formula,



in a solvent in the presence of an acid acceptor.

9. The process of claim 8, wherein the ratio of the number of moles of the pyrrolidine oxime derivative to the number of moles of the quinolone derivative ranges from one(1) to ten(10).

10. The process of claim 8, wherein said solvent is selected from the group consisting of acetonitrile, dimethylformamide, dimethylsulfoxide, pyridine, N-methylpyrrolidinone, hexamethylphosphoramide, ethanol, and aqueous mixtures thereof.

11. The process of claim 8, wherein said acid acceptor is selected from inorganic bases consisting of sodium hydrogen carbonate and potassium carbonate and organic bases consisting of triethylamine, diisopropylethylamine, pyridine, N,N-dimethylaniline, N,N-dimethylaminopyridine, 1,8-diazabicyclo-[5.4.0]undec-7-ene, and 1,4-diazabicyclo[2.2.2]octane.

12. The process of claim 8, wherein the reaction is carried out at a temperature ranging from room temperature to 200°C.

13. A process for preparing 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naph-

rrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid represented by the following formula:



or its isomer, methanesulfonate and hydrate of the methanesulfonate, which comprises reacting a quinolone derivative represented by the following formula,



in which X represents a halogen, with a protected pyrrolidine oxime derivative represented by the following formula,



in which P represents an amino-protecting group, in the presence of a base and then removing the amino-protecting group P from the resulting compound.

14. The process of claim 13, wherein the amino-protecting group is selected from the group consisting of formyl, acetyl, trifluoroacetyl, benzoyl, para-nitrobenzoyl, para-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, benzyloxycarbonyl, para-methoxybenzyloxycarbonyl, trichloroethoxycarbonyl, benzyl, para-methoxybenzyl, trityl and tetrahydropyranyl.

15. An antibacterial composition comprising as an active component the compound defined in claim 1 or 3, together with a pharmaceutically acceptable carrier.

16. The composition of claim 15 comprising 1 to 100mg of the compound defined in claim 1 or 3 in a unit dosage form.

ABSTRACT OF DISCLOSURE

The present invention relates to a novel quinolone compound having an excellent antibacterial activity. More specifically, the present invention relates to 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid represent by the following formula :



or its isomer.



FIG. 1



FIG. 2


Equilibrium Moisture Content (%)
12
10
8
6
4
2
0
23
31
41
51
62
75
Relative Humidity (%)

FIG. 3


12
10
8
6
4
2
0
Moisture Content (%)
23
33
43
52
64
75
Relative Humidity (%)
Moisture Content

FIG. 4



FIG. 5



FIG. 6



FIG. 7


Moisture Content (%)
12
10
8
6
4
2
0
0
5
10
20
30
60
Time (min)
Moisture Content (%)

FIG. 8


^exo
DSC
5
mW
3 Hydrate
Anhydride
40
60
80
100
120
140
160
180
200
220
240 c
LG CHEM. Biotech. I:preformulation
METTLER TOLEDO STARe System

FIG. 9



FIG. 10

JOINT DECLARATION FOR PATENT APPLICATION

As the below named inventor, we hereby declare that:

Our residence, post office address and citizenship are as stated below next to our names;

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled 7-(4-AMINOMETHYL-3-METHYLOXYIMINOPYRROLIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID AND THE PROCESS FOR THE PREPARATION THEREOF,

the specification of which

- ☐ is attached hereto.
- ■ was filed on April 4, 1997 as Application Serial Number 08/825,992 and was amended on April 4, 1997 (if applicable).

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

Prior Foreign Application(s)

We hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Country	Application Number	Date of Filing (day, month, year)	Date of Issue (day, month, year)	Priority Claimed Under 35 U.S.C. §119
Republic of Korea	94-13604	16 June 1994		yes
Republic of Korea	94-39915	30 December 1994		yes
Republic of Korea	94-39930	30 December 1994		yes

Prior United States Application(s)

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose materia information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior applicatior and the national or PCT international filing date of this application:

Application Serial Number	Date of Filing (Day, Month, Year)	Patent Number	Date of Issue (Day, Month, Year)	Status — Patented, Pending, Abandoned
08/490,978	15 June 1995	5,633,262	27 May 1997	Patented

And we hereby appoint, both jointly and severally, as our attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith the following attorneys who are all members of the Bar of the District of Columbia, their registration numbers being listed after their names:

Donald W. Banner, Registration No. 17,037; Harold J. Birch, Registration No. 16,527; Edward F. McKie, Jr., Registration No 17,335; William W. Beckett, Registration No. 18,262; Dale H. Hoscheit, Registration No. 19,090; Joseph M. Potenza, Registratio No. 28,175; Alan I. Cantor, Registration No. 28,163; James A. Niegowski, Registration No. 28,331; Joseph M. Skerpon, Registratio No. 29,864; Thomas L. Peterson, Registration No. 30,969; Nina L. Medlock, Registration No. 29,673; William J. Fisher, Registratio No. 32,133; Thomas H. Jackson, Registration No. 29,808; Franklin D. Wolffe, Registration No. 19,724; and Susan A. Wolffe Registration No. 33,568.

All correspondence and telephone communications should be addressed to:

Banner & Witcoff, Ltd.
Eleventh Floor
1001 G Street, N.W.
Washington, D.C. 20001-4597
Tel: (202) 508-9100

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of First Inventor	Chang Yong Hong		Date 7/4/1997
Full Name of First Inventor	Family Name HONG	First Given Name Chang Yong	Second Given Name
Residence & Citizenship	City Daejeon	State or Foreign Country Korea	Country of Citizenship Republic of Korea
Post Office Address	Post Office Address Lucky Apt. 6-205, 381-42, Doryong-dong, Youseong-ku	City Daejeon	State & Zip Code/Country Korea
Signature of Second Inventor	Young Kwan Kim		Date 7/4/1997
Full Name of Second Inventor	Family Name KIM	First Given Name Young Kwan	Second Given Name
Residence & Citizenship	City Daejeon	State or Foreign Country Korea	Country of Citizenship Republic of Korea
Post Office Address	Post Office Address Lucky Apt. 5-403, 381-42, Doryong-dong, Youseong-ku	City Daejeon	State & Zip Code/Country Korea
Signature of Third Inventor	Se Ho Kim		Date 7/4/1997
Full Name of Third Inventor	Family Name KIM	First Given Name Se Ho	Second Given Name
Residence & Citizenship	City Daejeon	State or Foreign Country Korea	Country of Citizenship Republic of Korea
Post Office Address	Post Office Address Lucky Apt. 7-105, 381-42, Doryong-dong, Youseong-ku	City Daejeon	State & Zip Code/Country Korea

■ Additional Inventors

Signature of Fourth Inventor	JAY-HYOK CHANG		Date '97.07.04
Full Name of Fourth Inventor	Family Name CHANG	First Given Name Jay Hyok	Second Given Name
Residence & Citizenship	City Daejeon	State or Foreign Country Korea	Country of Citizenship Republic of Korea
Post Office Address	Post Office Address Lucky Dormitory 312, 386-1, Doryong-dong, Youseong-ku	City Daejeon	State & Zip Code/Country Korea

Signature of Fifth Inventor	Choi Hoon		Date '97.07.04
Full Name of Fifth Inventor	Family Name CHOI	First Given Name Hoon	Second Given Name
Residence & Citizenship	City Daejeon	State or Foreign Country Korea	Country of Citizenship Republic of Korea
Post Office Address	Post Office Address Lucky Apt. 5-404, 381-42, Doryong-dong, Youseong-ku	City Daejeon	State & Zip Code/Country Korea

Signature of Sixth Inventor	Do-Hyun Nam		Date '97.07.04
Full Name of Sixth Inventor	Family Name NAM	First Given Name Do Hyun	Second Given Name
Residence & Citizenship	City Daejeon	State or Foreign Country Korea	Country of Citizenship Republic of Korea
Post Office Address	Post Office Address Expo Apt. 508-603, Jeonmin-dong, Youseong-ku	City Daejeon	State & Zip Code/Country Korea

Signature of Seventh Inventor	Ae-Ri Kim		Date 97 07 04
Full Name of Seventh Inventor	Family Name KIM	First Given Name Ae Ri	Second Given Name
Residence & Citizenship	City Daejeon	State or Foreign Country Korea	Country of Citizenship Republic of Korea
Post Office Address	Post Office Address LG Yeonrip #201, 388-11, Doryong-dong, Youseong-ku	City Daejeon	State & Zip Code/Country Korea

■ Additional Inventors

LAW OFFICES
BANNER & WITCOFF, LTD.
1001 G STREET, N.W.
WASHINGTON, D.C. 20001-4597
(202) 508-9100

Signature of Eighth Inventor	Jin Hwa Lee		Date 97.07.04
Full Name of Eighth Inventor	Family Name LEE	First Given Name Jin Hwa	Second Given Name
Residence & Citizenship	City Daejeon	State or Foreign Country Korea	Country of Citizenship Republic of Korea
Post Office Address	Post Office Address LG Chemical Dormitory #325, 386-1, Doryong-dong, Youseong-ku	City Daejeon	State & Zip Code/Country Korea
Signature of Ninth Inventor	Ki Sook Park		Date 97.07.04
Full Name of Ninth Inventor	Family Name PARK	First Given Name Ki Sook	Second Given Name
Residence & Citizenship	City Daejeon	State or Foreign Country Korea	Country of Citizenship Republic of Korea
Post Office Address	Post Office Address LG Chemical Dormitory #107, 386-1, Doryong-dong, Youseong-ku	City Daejeon	State & Zip Code/Country Korea

LAW OFFICES
BANNER & WITCOFF, LTD.
1001 G STREET, N.W.
WASHINGTON, D.C. 20001-4597
(202) 508-9100